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Meeting Report of the European Histamine Research Society
G. Sturman
This year’s meeting was in Florence, Italy at the kind invi-
tation of Professor Emanuela Masini. This is the fourth time
that histaminologists havemet in Florence and the second one
that Emanuela has organised, the first being in 2007. The two
previous Florence meetings had been organised by one of our
HonoraryMembers, Pier Francesco Mannaioni and they took
place in 1984 and 1975. Most of the delegates arrived on the
Wednesday and this year there were 94 participants and 14
accompanying persons registered and they represented nearly
20 countries (mostly from Europe but also from North, South
and Central America, Japan and Korea as well as some of the
Middle Eastern countries). Some regular attendees could not
attend and they were missed but a big welcome was made to
all the new visitors, who we hope will return to future
meetings. The Council met as usual late afternoon. This year
the meeting started formally on the Wednesday evening with
the Opening Ceremony for the 45th meeting of our society in
the Rettorato Lecture Hall of the University of Florence. We
were welcomed by Professor Marco Bindi, Dean for National
and International Research of the University of Florence, and
Professor Alessandro Mugelli, Elected President of Italian
Pharmacological Society. Our hostess, Professor Emanuela
Masini and Paul Chazot, our President then talked about this
meeting and paid tribute to Piero Mannaioni, an Honorary
Member of the EHRS and now retired from Florence
University. Then we listened to a lecture from Professor
Donatella Lippi, Professor of History ofMedicine at Florence
University entitled ‘‘Life and Death of the Medici Family’’.
She talked about this powerful Florentine family and the
forensic work which has been undertaken on their remains.
After this ceremony we then walked a short distance to the
‘‘Giardino de’ Semplici’’ the Botanical Garden of the
University which we wandered through before being taken to
the University’s Museum of Minerals and Stones. Then we
returned to the Botanical Gardens for the Welcome Recep-
tion. Here we greeted old and new friends and exchanged
news during the rest of the evening but also were able to
marvel at the various plants on display in the Botanical
Gardens—it was an excellent start to the meeting.
This year’s meeting was held in the ‘‘Maglio Cloister’’,
which had been a convent for Dominican Nuns, but is now
used by the Italian Army as their Medical School/Head-
quarters. On the Thursday morning, during the Opening
Session we were formally welcomed by Emanuela who
thanked Director of the Maglio Cloister for the use of this
venue. Also thanks were given to all the various helpers. She
also reported that there had been 79 abstracts submitted
giving us 5 oral sessions, 5 poster sessions and also 5 invited
speakers. Then we were welcomed again by our President,
Paul Chazot, who then gave out the student bursaries cer-
tificates and € 500 for each of the 13 student members. The
El-Sayed Assem family very generously sponsored two stu-
dents while the rest were sponsored by our society.
Then we had the Honorary Membership ceremony where
Associate Professor Anita Sydbom of Karolinska Institute,
Sweden was presented with her official certificate beauti-
fully written in Latin and sporting the society’s official seal.
The oration was given by Madeleine Ennis and Gill Stur-
man who spoke about many facets which Anita has given to
the society and this included also the musical aspect. Thus it
was fitting that this oration ended with a song dedicated to
Anita. Anita then thanked the society for this honour. The
scientific programme began with the first plenary lecture
being the G. B. West lecture which was given by Patrizio
Blandina of Florence University and was entitled ‘‘The role
of histamine in the memory of emotionally-salient experi-
ences’’. He was introduced by Pertti Panula, Finland. At the
end of this very interesting lecture, Patrizio was presented
with a copy of GB West’s autobiography—‘‘A Handful of
Luck’’. This lecture was an excellent start to the first sym-
posium which was on histamine and the Central Nervous
System (CNS). Just before lunch we had the second plenary
lecture and this was introduced by Madeleine Ennis. Pro-
fessor Hiroyuki Fukui of Tokushima University, Japan gave
a very enlightening lecture on ‘‘Histamine H1 receptor gene
as a sensitive gene of nasal hypersensitivity and clinical
significance of antihistamines’’.
In the afternoon there were two poster sessions; both on
histamine and the CNS and also oral presentations on
histamine and inflammatory responses before the third
plenary lecture which was delivered by Holger Stark,
Dusseldorf University, Germany and introduced by Astrid
Sasse, Ireland. Holger talked about ‘‘The development of
histamine H3 receptor antagonists from the bench to the
bedside and back again’’. Then we went for a very inter-
esting visit to the Cloister of Basilica della Santissima
Annunziata (Basilica of the Most Holy Annunciation)
which is a Renaissance-styled basilica and the Chapel of
the Artists. The buildings were founded in 1250 by the
seven original members of the Servite Order and many
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artists are buried in its vault. The Florentine brides tradi-
tionally visit this shrine depicting the Annunication to
leave their bouquets. Here we were had a very informative
guided tour and saw a number of paintings being restored.
Friday started with another plenary lecture and this one
was given by Ivan Izquierdo, Pontificial Catholic Univer-
sity of Porto Alegre, Brazil. Beatrice Passani gave the
introduction. Ivan told us about ‘‘The involvement of his-
tamine in memory consolidation’’. This was followed by
the third symposium which was on histamine receptors.
After coffee, we had a Round Table on the ‘New Insights in
Histamine and Cells of Inflammation’. This was chaired by
Ekaterini Tiligada, Greece and Carlo Riccardi, Italy and
part of this round table was an invited lecture given by
Francesca Levi Schaffer, The Hebrew University of Jer-
usalem, Israel on ‘‘Mast cells the masterminds of allergic
inflammation: What is now out there to inhibit their func-
tion?’’ The morning ended with another poster session on
Histamine Ligands in Metabolism and Adverse Effects.
After this session, we ate our packed lunches before
boarding coaches for our trip to Lucca. We drove north-
westwards from Florence to the Tuscan walled town of
Lucca. Although we were driven on motorways to Lucca,
we were able to see a little of the Tuscan countryside. Our
first impression of Lucca was its huge wall which circles
the old town. Here we were given a guided walking tour of
Lucca. Initially we were taken for a short walk on the wall
which sports a road of over 4 km in length. Then we
descended from the wall and went into the old town. We
were taken to Lucca’s Cathedral (Duomo di San Martino).
The Duomo contains the most precious relics of Lucca; the
Holy Face of Lucca (a cedarwood crucifix), an image of
Christ as well as the sculpture of the tomb of Ilaria del
Carretto by Iacopo della Quercia. We heard about and saw
many of the churches in Lucca and also visited Piazza the
Anfiteatre, which has been restored/built in the ovoid shape
of a Roman Amphitheatre making it into a modern square.
Finally we were taken to the Real Collegium, the old
convent of Saint Frediano Basilica, which under the Grand
Duke Ferdinand in the Eighteen century became a Lyceum,
where we had our dinner.
The following day the meeting started with presentations
from our younger members (PhD students or not more than
3 year’s post-doctoral research) who had been selected to
give presentations for the EHRS Young Investigator Award
(YIA). This competition was sponsored by Janssen Phar-
maceutical Company. It was a very difficult task for the
judges to differentiate between these nine excellent pre-
sentations. The winner was Roberta Fabbri (Florence, Italy)
for her presentation entitled ‘‘Brain histamine modulates
inhibitory-avoidance memory recall by activating H1 re-
ceptors in hippocampal CA1’’ and the runner-up was
Reggie Bosma (Amsterdam, The Netherlands) for her
presentation entitled ‘‘Residence time of antihistamines and
its effect on signaling of the histamine H1 receptor’’. The
rest of the finalists were given Highly Commended Cer-
tificates. During the coffee break we had a group photo
taken and then during the lunch, the Early Stage
Researchers met with two of the Council Members (Arianna
Rosa and Vanina Medina) to talk to about their ideas/wishes
for the society. In the afternoon the final poster presentation
sessions which were on Inflammation and New Therapeutic
options took place. The final symposium of the meeting was
on ‘‘Histamine and Future Clinical Development’’.
After this session there was a further viewing of the best 7
posters as judged by the poster jury (Paul Chazot, Jules
Heuberger, Jerzy Jochem, Linda Kay, Cecilia Lanzi, Vanina
Medina, Gustavo Provensi, Anwar Rayan, Arianna Rosa and
Francisca Sa´nchez-Jime´nez)who had beenworking very hard
during the meeting and as usual had a difficult task in identi-
fying winning posters for the poster competition. Eventually
first prize was given to Kristine Rossbach et al., from Han-
nover, Germany with the poster entitled ‘‘Anti-inflammatory
effect of a combined treatment with an H1R antagonist and an
H4R antagonist in a mouse model of atopic dermatitis’’, sec-
ond to Sabrina Rahman et al., from Amsterdam, The
Netherlands with the poster entitled ‘‘Differences in b-ar-
restin2 recruitment by human H3R isoforms as determined by
Enzyme Fragment Complementation’’ and third prize jointly
went to Tadaho Nakamura et al., from Sendai, Japan with the
poster entitled ‘‘Electroencephalogram of H1KO mice under
isoflurane anesthesia’’ and to Katrin Schaper et al., from
Hannover, Germany with the poster entitled ‘‘Impact of his-
tamine on type 2 immune response’’. The authors of the three
other posters short listed were given Highly Commended
Certificates.
After this we held our General Assembly where the main
issues discussed were the updating of our statutes and the
website. This was followed by our traditional Farewell
Dinner which took place in the prestigious historical Palazzo
Budini Gattai in the heart of Florence. During the live
concert by Les Moquettes and the Dirty Boots, the Award
Ceremony with certificates and prizes were given out. All
YIA finalists and poster prize winners received a souvenir
from the organising committee. Then as usual we had our
singing session, beginning with ‘‘Anita’s Thank You Song’’
(sung to the tune of ‘Oh Susanna’) as a big thank you to
Emanuela and her team for the excellent and memorable
meeting. After this we sung our EHRS Anthem, before
saying ‘au revoir’ to our many ‘histaminergic’ friends.
Our thanks are given to all the Italian histaminologists,
especially Emanuela Masini and Beatrice Passani for the
excellent meeting. The next meeting will be held in
Amsterdam, The Netherlands (10–13 May, 2017) and will
be a joint meeting with the Japanese Histamine Research
Society. It will be organised by Rob Leurs and colleagues.
The European Histamine Research Society S3
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London, SE1 1UL. E-mail: sturman.gill@gmail.com
Participants of the 2016 meeting of the EHRS.
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Honorary Memberships in the European Histamine Research Society
M. Ennis, G. Sturman
There are three types of membership in the EHRS: ordi-
nary, corporate and affiliated, and honorary (life). The
highest award is that of honorary membership which is
only given to very special people. To obtain honorary
membership, the person has to be elected by over two-
thirds of the ordinary members at the General Assembly.
There are only 14 current Honorary Members of the
Society; Madeleine Ennis, Agnieszka Fogel, Robin
Ganellin, Helmut Haas, Zsuzsanna Husti, Piero Mannaioni,
Emanuela Masini, Bruno Mondovi, Fred Pearce, Jean-
Charles Schwartz, Henk Timmerman, Ingrid Olhagen-
Uvna¨s, Takehiko Watanabe and Jean West. Former (now
sadly deceased) Honorary Members of this society include
Sir James Black, Franc Erjavec, Wilfried Lorenz, Czeslaw
Maslinski, Wolfgang Schmutzler, B}orje Uvna¨s and Geof-
frey West. At this meeting, the society awarded Honorary
Membership to a special person who has contributed sig-
nificantly to the EHRS over the years and she is Assistant
Professor Anita Sydbom of the Karolinska Institute,
Sweden.
The oration for Anita was given by two of her closest
EHRS friends; Madeleine Ennis and Gill Sturman. Anita
studied Chemistry, Zoology and Microbiology at the
University of Stockholm, graduating with a Bachelor of
Science in December 1966. She then began her life-long
association with the Karolinska Institute working with her
scientific father and mentor, the late Professor Bo¨rje
Uvna¨s. This was a very fruitful collaboration and she
obtained her PhD in 1982. Her thesis was entitled: Ana-
phylactic histamine release from isolated rat mast cells:
Pharmacological and methodological studies and several
honorary members of the EHRS wrote to her congratulat-
ing her on this fine piece of work. The slight delay was
caused by the birth of three of her four children during her
PhD studies! She continued her research in the Karolinska
Institute, starting another long-term collaboration with
Sven-Erik Dahle´n and also taught pharmacology. In 1989,
to further her career she started studying medicine and
discovered another passion, helping patients. She has
continued with this dual role of working as a researcher and
a medical doctor. However, Anita never makes things easy;
her clinical work is in Funa¨sdalen a mere 568 km north of
Stockholm!
Anita has been a member of the EHRS Member since
1979 and participated in 34 meetings and presenting her
research, only missing a very few meetings due to illness or
pregnancy. She has held many positions of responsibility
within the society: 1983–1984, 1989 Vice National Sec-
retary, 2003–2006 Council member, 2006–2012 President
of the EHRS, 2012–2013 Past President of the EHRS and
she took over as President in 2013/2014 due to the serious
illness of the President, Paul Chazot. In 2008, she orga-
nized the Stockholm EHRS meeting. Anita is also a great
poet and singer. She has been updating the EHRS anthem
annually since 1990 and since 1988 has written a special
song for each of the meetings. In 2008, we wrote one for
her as she did not want to write one for herself! Many of
the younger members will know that she is a great pho-
tographer making sure that the society has a photo of every
member attending the meetings. Anita is a fantastic sup-
porter and ambassador for the society and rightly deserves
being elected an Honorary Member of the European His-
tamine Research Society.
Department of Pharmacology and Therapeutics, School of
Biomedical and Health Sciences, Kings College London,
London SE1 1UL. E-mail: sturman.gill@gmail.com
The presentation of Honorary Membership to Associate Professor Anita
Sydbom by Paul Chazot, President of the EHRS with Professor Emauela
Masini, hostess for this meeting.
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Immunological aspects of histamine
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HISTAMINE H1 RECEPTOR GENE AS




Nasal hypersensitivity is a representative incurable disease.
Antihistamines are the first choice for the therapy of this
disease. Antihistamines target histamine H1 receptor
although the mechanism of antihistamines to alleviate the
symptoms remains to be elucidated. The mechanism of
histamine H1 receptor-mediated H1 receptor up-regulation
was recently discovered. The significant correlation
between nasal symptom scores and level of H1 receptor
mRNA in nasal mucosa was also observed in patients with
pollinosis, suggesting that the H1 receptor gene is an
allergic disease-sensitive gene. The H1 receptor up-regu-
lation was induced by the activation of protein kinase
C-delta (PKCd) and downstream elevation of H1 receptor
gene expression.
(-)Maackiain isolated from Kujin, an anti-allergic
Kampo medicine found to target heat shock protein 90
(hsp90), dissociated Hsp90-PKCd complex and suppressed
H1 receptor gene expression. Alleviation by (-)maackiain
and Hsp90 inhibitors of hypersensitivity symptoms also
suggests that the H1 receptor gene is an allergic disease-
sensitive gene. The elucidated pathological mechanism is
thought to be a good tool for the establishment of nasal
hypersensitivity therapy with highest satisfaction.
Department of Molecular Studies for Incurable Diseases,
Institute of Biomedical Sciences, Tokushima University,
Tokushima, Japan. E-mail: hfukui@tokushima-u.ac.jp
MAST CELLS THE MASTERMINDS OF ALLERGIC
INFLAMMATION: WHAT IS NEW OUT THERE TO
INHIBIT THEIR FUNCTION?
F. Levi-Schaffer, R. Singh Gangwar, M. Seaf, L. Karra,
N. Landolina
Mast cells (MCs) are the primum movens of the allergic
response. Moreover we have defined a pro-inflammatory
crosstalk (the Allergic Effector Unit, AEU) between MCs
and the infiltrating eosinophils (Eos) that stresses the role
of MC role in late phase and chronic development of
allergic inflammation. Therefore, inhibition of MCs is a
main pharmacological target to limit allergy and possibly
other MC driven diseases. We aimed to define activating
(AR) and inhibitory (IR) receptors on MCs as druggable
options for the treatment of allergic diseases. We used
human cord blood derived MCs (CBMC) and mouse bone
marrow derived MCs (BMMC). Mice models were atopic
dermatitis (AD), allergic asthma (AA), allergic rhinitis
(AR) and allergic (AP) and S. aureus enterotoxin B (SEB)
induced peritonitis (SEB-P). FC, WB, RT-PCR, various
functional assays for in vitro receptor studies were used. In
the in vivo models, inflammatory infiltrate and specific
markers of the disease were followed. We defined CD48, a
GPI CD2 family receptor, as a main AR expressed on MCs
that can be activated by the binding to its high affinity
ligand 2B4 as expressed on Eos and by S. aureus/SEB a
known infecting pathogen of allergic diseases and by
specific mAbs. Its blocking or absence (CD48-/- BMMC)
decreased significantly MCs activation. Similarly AD or
AP or SEB-P disease markers were significantly reduced in
CD48-/- mice. We also described CD300a and Siglec-7
as main IRs on MCs. The activation of these receptors
carried out by specific mAbs downregulated the in vitro
MCs functions by a distinct ITIM-mediated signal trans-
duction pathway. Moreover in a CD300a-/- model of AP
inflammation was significantly enhanced. Blocking of
CD48 on MCs can be a therapeutic option in selected AD
and asthmatic patients. Siglec-7 and CD300a activation by
mAbs can be a more general option to inhibit MC activa-
tion in any allergic and non-allergic disease in which MCs
have an activated phenotype.
The Hebrew University of Jerusalem, Jerusalem, Israel. E-
mail: francescal@ekmd.huji.ac.il
TREATMENT WITH ANTIHISTAMINES IN
COMBINATION WITH SUPLATAST TOSILATE
MARKEDLY ALLEVIATED NASAL SYMPTOMS IN
TOLUENE-2,4-DIISOCYANATE-SENSITIZED RATS
T. Wakugawa, H. Mizuguchi, T. Kadota, A. Sawada,
T. Kominami, Y. Kitamura, N. Takeda, H. Fukui
Antihistamines inhibit histamine signalling by blocking the
histamine H1 receptor (H1R) or suppressing H1R signalling
as inverse agonists. The H1R gene is upregulated in
patients with pollinosis; its expression level is highly cor-
related with the nasal symptom severity. Thus,
antihistamines that suppress H1R gene expression are
widely used as allergy treatments. However, long-term
treatment with antihistamines does not completely resolve
toluene-2,4-diisocyanate (TDI)-induced nasal symptoms,
although it can decrease TDI-induced upregulation of H1R
gene expression to the basal level, which suggests that
other types of signalling are responsible for the pathogen-
esis of the allergic symptoms. Here, we show that treatment
with antihistamines and suplatast tosilate markedly allevi-
ates nasal symptoms in TDI-sensitized rats. Suplatast
(500 lM) suppressed ionomycin/phorbol-12-myristate-13-
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acetate-induced upregulation of IL-2 gene expression in
Jurkat cells (65.1 ± 6.7 %, N = 4, P\ 0.01 1-way
ANOVA), in which calcineurin (CN)/Nuclear factor of
activated T-cells (NFAT) signaling is known to be
involved in IL-2 gene expression. Immunoblot analysis
demonstrated that suplatast inhibited binding of NFAT to
DNA (basal level). Furthermore, suplatast suppressed
ionomycin-induced IL-9 mRNA upregulation in RBL-2H3
cells, in which CN/NFAT signalling is also involved. Data
suggest that combined therapy of antihistamines and
suplatast could be effective in alleviating nasal symptoms
in allergic rhinitis. The mechanism underlying this therapy
appears to be the suppression of both H1R and CN/NFAT
signalling by antihistamines and suplatast, respectively.
Departments of Molecular Pharmacology, and of Oto-
laryngology, and of Molecular Studies for Incurable
Diseases, Institute of Biomedical Sciences, Tokushima
University Graduate School, Tokushima, Japan. E-mail:
c401531023@tokushima-u.ac.jp
HISTAMINE IN INFLAMMATION—THE
INVOLVEMENT OF HISTAMINE H4 RECEPTOR IN
HUMAN EOSINOPHILS ADHESION TO
ENDOTHELIUM
M. Grosicki, S. Chłopicki, K. Kiec´-Kononowicz
Histamine is known to be involved in inflammatory
responses that include cellular chemotaxis, migration and
trafficking. Nevertheless, the relative role of histamine and
histamine receptors in the mechanisms of leukocyte adhe-
sion to endothelial cells remains elusive. Therefore, the aim
of this study was to examine the effect of selective his-
tamine receptors ligands on eosinophil adhesion to the
endothelium. Highly purified eosinophils (98 %) were
isolated from the human peripheral blood. Their viability
and functionality were validated in several tests prior to the
experiments. Eosinophil adhesion to endothelium cells was
evaluated during eosinophil co-culture with human
Ea.hy.926 endothelium cell lines, under static conditions.
In adhesion assays, the cells were exposed to: fMLP, his-
tamine, and histamine receptor ligands that included: H1
receptor antagonist/inverse agonist—diphenhydramine and
mepyramine, H2 receptor antagonists—famotidine and
ranitidine, H3 receptor antagonist—pitolisant, H4 receptor
antagonists—JNJ7777120 and H3/H4 antagonist—thiop-
eramide. Both histamine and fMLP significantly
(P\ 0.001) increased the number of eosinophils that
adhere to endothelium, in dose-dependent manner (with
EC50 of 1.36 and 1.42 lM respectively). Among the
selected histamine receptors ligands only JNJ7777120 and
thioperamide had direct effect on eosinophil adhesion to
endothelial cells, decreasing the number of adherent cells
in presence of histamine (with IC50 value of 0.7 and
1.9 nM respectively). The H4 receptors antagonists them-
selves were ineffective in eosinophil adhesion. No
additional effect from histamine H1 and H2 receptor ligands
was detected when exposed to high histamine concentra-
tions. 4-methylhistamine, the selective histamine H4
receptor agonist, increased the number of adherent cells
with similar effectives to histamine (EC50 of 0.63 lM).
These data demonstrate that histamine H4 receptor plays a
dominant role in histamine-induced eosinophil adhesion to
the endothelium.
Supported by National Science Centre grant No.: DEC/
2014/13/N/NZ7/00897 and DEC/2011/02/A/NZ4/00031.
Jagiellonian University Medical College, Faculty of
Pharmacy, Department of Technology and Biotechnology
of Drugs, Cracow, Poland. E-mail: marek.grosicki@
uj.edu.pl
HISTAMINE-GENERATING hdcA+ L. REUTERI
SUPPRESSES INFLAMMATION AND REGULATES
MYELOPOIESIS IN MOUSE MODELS
B. P. Ganesh, A. Hall, M. Whary, J. G. Fox, J. Versalovic
Probiotics may beneficially affect the disease course of
patients with chronic immune-mediated disorders like
inflammatory bowel disease and colorectal cancer (CRC)
via modulation of host immune responses. A recent
pangenomic study showed that human-derived clade II L.
reuteri strains contained a complete chromosomal histidine
decarboxylase (hdc) gene cluster (genes hdcA, hdcB, hdcP)
and have the genetic capacity to convert histidine to his-
tamine. In our lab we found L. reuteri 6475 (clade II)
derived-histamine suppressed TNF production by human
myeloid cells. In addition, we also showed that adminis-
tration of L. reuteri to HDC deficient mice bearing
inflammation-associated colon cancer (IaCC) showed
suppression of inflammatory cytokines (mainly IL-6, IL-
22, IL-1a and TNF). Apart from suppression of the
inflammatory response, CD11b+ Gr-1+ immature myeloid
cell (IMCs) populations were reduced in the spleen and
bone marrow of hdcA+ L. reuteri administered to HDC KO
mice bearing IaCC compared to HDC KO IaCC mice with
hdcA- L. reuteri. These changes correlated with reduced
tumor numbers in HDC KO mice. However, L. reuteri
lacking histidine decarboxylase (hdcA mutant) were unable
to produce histamine and did not protect HDC KO mice
from IaCC. However, L. reuteri 6475-derived histamine
and its ability to suppress inflammation and reduce IaCC
are not well understood. We therefore hypothesized that L.
reuteri derived-histamine down-regulates histamine
The European Histamine Research Society S9
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receptor 1(H1R) and stimulates H2R, thereby suppressing
inflammation. We used Swiss-Webster WT and BALB/c
WT germ-free mice mono-associated with L. reuteri wild-
type or the L. reuteri hdcA mutant strain. Our results
showed significant reduction of IL-6 expression in the GF
mice receiving L. reuteri WT and hdcA mutant strains,
n = 10 (5 males and 5 females each). In addition, we found
that both WT and mutant strains can produce diacylglyc-
erol kinase (dagK), inhibiting DAG signaling downstream
and potentially blocking H1R downstream signaling.
Moreover, we showed that IL-6 is not suppressed in dagK
mutant L. reuteri colonized GF mice. We also observed
that dagK is a secretory protein by L. reuteri 6475 and was
quantified using liquid chromatography mass spectrometry
(LC–MS/MS) analysis. In conclusion, L. reuteri
6475-derived histamine induced H2R downstream signal-
ing and suppressed inflammation by inhibiting H1R
downstream signaling via dagK secretory enzyme in the
host intestine.
Dept. of Pathology and Immunology, Baylor College
of Medicine, Houston, Texas, USA. E-mail:
bhanu.ganesh@bcm.edu
HISTAMINE REGULATES THE ACTIN
CYTOSKELETON IN HUMAN TLR4-ACTIVATED
mDCs TUNING CD4+ T LYMPHOCYTE
RESPONSES
A. Aldinucci, E. Bonechi, C. Manuelli, D. Nosi, E. Masini,
M. B. Passani, C. Ballerini
Histamine differentially regulates the polarizing ability of
Dendritic Cells (DCs) after stimulation through Toll-like
receptors (TLRs), although the mechanisms are not fully
understood. TLRs are a class of receptors critical in host
defense that specifically detect pathogen-associated
molecular patterns and their action has been associated
with loss of tolerance and pathogenesis of chronic
inflammation, autoimmunity and allergy. In this study we
investigated the effects of histamine (10 lM; for 6 days)
on the innate immune reaction during the response of
human monocyte-derived DCs (mDCs; n = 5) to different
TLR stimuli: LPS, specific for TLR4 and Pam3Cys,
specific for the heterodimer molecule TLR1/TLR2. We
investigated mDC phenotype, cytokine production, and
Th0 stimulatory and polarizing ability, together with
analysis of the cytoskeleton of mDCs by confocal micro-
scopy, and RT-PCR expression of Rac1/CdC42 Rho
GTPases, responsible for actin remodeling. Our results
show that histamine selectively modifies actin cytoskeletal
organization induced by TLR4, but not TLR2, and this
correlates with increased IL-4 production by primed T cells
(p\ 0.05). We also demonstrate that histamine-induced
cytoskeleton organization is mediated by down-regulation
of small Rho GTPase CdC42 and the protein target PAK1,
but not by down modulation of Rac1. Independently of
actin remodeling, histamine down-regulates IL12p70 and
CXCL10 production in mDCs after TLR2 and TLR4
stimulation. We also observed a trend of IL-10 up-regu-
lation that did not reach statistical significance. In
conclusion, our data show that histamine differently shapes
mDC TLR4 and TLR2 responses and we propose that,
besides antigen presentation, costimulatory molecules and
CKs milieu, this effect is also mediated by cytoskeletal
rearrangements.
Department of Neuroscience, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-
ence, Florence Italy. E-mail: clara.ballerini@unifi.it
HISTAMINE H2 RECEPTOR STIMULATION UP-
REGULATES TH2 CHEMOKINE CCL17
PRODUCTION IN HUMAN M2 MACROPHAGES
S. Mommert, K. Gregor, H. Stark, R. Gutzmer, T. Werfel
Histamine receptors are possible therapeutical target
structures for the treatment of atopic dermatitis. In allergic
skin diseases such as atopic dermatitis, macrophages are
attracted into tissue and exposed mainly to Th2 cytokines
and also to histamine which is released in the skin during
allergic reactions. In this study, we investigated the role of
histamine on human monocyte derived M2 macrophages
differentiated in the presence of M-CSF and activated with
IL-4 or IL-13. H1R- H2R- and H4R mRNA expressions
were measured on fully differentiated and IL-4 activated
monocyte derived M2 macrophages by quantitative PCR.
We observed that the activation with IL-4 led to a signif-
icant up-regulation of the H2R and H4R at mRNA level
(p\ 0.05) in M2 macrophages. The activation of M2
macrophages with IL-4 or IL-13 resulted in higher
expression levels of the Th2 cell attracting chemokines
CCL22 and CCL17 at mRNA- and protein level. Interest-
ingly, stimulation with histamine led to a significant more
than two fold further up-regulation of CCL17 expression
(p\ 0.01) whereas the expression of CCL22 was not
affected by histamine. To show which histamine receptor
was responsible for the up-regulation of CCL17, we stim-
ulated the H1R, H2R and H4R on human IL-4 or IL-13
activated M2 macrophages. Of note, we observed that the
effect was attributed to the H2R. The stimulation of the
H2R with the selective H2R agonist amthamine and
4-methylhistamine (H2R/H4R agonist) led to a significant
up-regulation of the CCL17 expression at mRNA- and
protein level (p\ 0.01) in IL-4 or IL-13 activated M2
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macrophages which could convincingly be blocked by pre-
incubation with the specific H2R antagonist ranitidine. In
summary we show a new function of the H2R by up-reg-
ulating the Th2 attracting chemokine CCL17 in human M2
macrophages which might lead to a pronounced attraction
of CCR4 expressing Th2 cells into the site of inflammation
and provide evidence for a role of histamine to support a
Th2 dominated milieu. This might have an impact on the
course of atopic dermatitis and for the treatment of the
disease.
Department of Dermatology and Allergy, Hannover
Medical School, 30625 Hannover, Germany. E-mail:
mommert.susanne@mh-hannover.de
NEW INSIGHTS INTO THE INTRACELLULAR
CONTROL OF IgE-DEPENDENT HISTAMINE
RELEASE FROM HUMAN BASOPHILS
B. F. Gibbs
Human basophils rapidly release histamine and other
inflammatory and immunomodulatory mediators upon
high-affinity IgE-receptor crosslinking and thereby play a
crucial role in the pathogenesis of allergic diseases. While
the presence of allergen-specific IgE on these cells is an
important determinant of basophil-mediated allergic
responses, it does not necessarily predict the severity of
clinical symptoms of allergy per se. The aim of this study
was to shed light on intracellular signals which are asso-
ciated with the control of human basophil reactivity.
Basophils were obtained from buffy coats purchased from
the NHS Blood and Transplant service (following research
ethics approval; REC 12/WM/0319) and highly purified (to
over 90 % purity) by negative selection and magnetic cell
sorting. Cells were incubated with IgE-dependent triggers,
together with unstimulated controls, for varying periods
after which histamine releases as well as intracellular sig-
naling protein expressions were assessed by
spectrofluorometric autoanalysis and Western blotting,
respectively. We observed that constitutive SHIP-1 phos-
phorylation (but not total SHIP-1 or Syk expressions) in
unstimulated basophil preparations correlated closely with
maximum basophil responses in terms of histamine release
to anti-IgE. Moreover, there was a striking inverse corre-
lation between basophil responsiveness to IgE-dependent
stimulation and expression of the sarcoplasmic reticulum
Ca2+-ATPase (SERCA2), a protein which controls intra-
cellular calcium mobilization. These results clearly show
that early excitatory or inhibitory signal transduction
pathways are not the only mechanisms that determine the
magnitude of IgE-dependent histamine release in basophils
but that regulators of intracellular calcium mobilization
also have critical input in allergic effector cell reactivity.
Upregulation of SERCA2 could therefore be considered as
a novel therapeutic approach in allergic effector cell-me-
diated diseases.
Medway School of Pharmacy, University of Kent, Chatham
Maritime, UK. E-mail: b.f.gibbs@kent.ac.uk
NEUROINFLAMMATORY PATHWAY: ROLE OF
NEURONAL AND NON-NEURONAL CELLS IN THE
PNS AND CNS
S. Cuzzocrea
Neuroinflammation represents the response of the CNS to
altered homeostasis. It is primarily mediated by the con-
tribution of one/two cell systems: glia, lymphocytes,
monocytes and macrophages of the hematopoietic system.
Neuroinflammation can be triggered by classical factors
such as infection, autoimmunity and toxins but also by
toxic stimuli or psychological stress. In the CNS and PNS,
glia and neurons, together with endothelial cells of the
microvasculature, release cytokines and express their
cognate receptors. The physiological functions of cytokines
include neurite outgrowth, neurogenesis, neuronal survival
and synaptic pruning during brain development. Moreover,
they regulate the strength of synaptic transmission and
synaptic plasticity. On the basis of current knowledge, a
novel therapeutic approach to the treatment of neuronal
diseases will be considered. Preclinical models of trauma
or neurodegenerative diseases are employed to study the
network involved in neuroinflammatory mechanisms. The
complexity of neuroinflammatory and neurodegenerative
diseases has hampered the identification of pharmacologi-
cal agents able to ameliorate outcomes after damage. In
this context, a new formulation composed of co-ultrami-
cronized palmitoylethanolamide (PEA, an endogenous
fatty acid amide signaling molecule) together with the
flavonoid luteolin (Lut, co-ultraPEALut) has been
employed. Due to the complex nature of the injury the best
approach is provided by a combination of many therapeutic
strategies to counteract the different aspects of the damage.
Neuroprotection pertains to the preservation of the spared
neurons and their processes following the injury. Neu-
roregeneration aims to modulate the lesion site
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environment to promote axonal regrowth. Neurorehabili-
tation has demonstrated beneficial effects at cellular and
molecular levels.
Dipartimento di Scienze Chimiche, Biologiche, Farma-
ceutiche e Ambientali, Universita` degli Studi di Messina,
Messina, Italy. E-mail: salvator@unime.it
CHARACTERIZATION OF THE ISOFORM OF
CYCLOOXYGENASE THAT MEDIATES THE
GENERATION OF PROSTAGLANDIN D2 FROM
HUMAN LUNG MAST CELLS
B. Baothman, J. Smith, L. Kay, P. Peachell
Mast cells are known to be the principal source of histamine
in the body but they are also a very rich source of pros-
taglandin D2 (PGD2). Our previous studies have shown that
activation of human lung mast cells by either anti-IgE or the
growth factor, Stem Cell Factor (SCF), leads to the genera-
tion of high levels of PGD2. The enzyme cyclooxygenase
(COX) is central to the generation of PGD2. COX generates
intermediates from arachidonic acid that are then acted on by
PGD2 synthase. COX exists as two main isoforms COX-1
and COX-2. The aim of this study was to identify which
COX isoform is responsible for PGD2 generation from
human lung mast cells. Mast cells were isolated from human
lung tissue and purified by flotation over Percoll and
immunomagnetic bead separation (85-98 % purity). The
cells were activated with SCF (100 ng/ml) or anti-IgE (2 lg/
ml) and the release of PGD2, histamine, and cysteinyl-leu-
kotrienes was assessed by spectrofluorometry and ELISA.
The effects of COX inhibitors, indomethacin (non-selec-
tive), FR122047 (COX-1 selective) and celecoxib (COX-2
selective) on mediator release were determined. Purified
mast cells were solubilised and used to determine the
expression of COX-1 and COX-2 by RT-PCR and Western
blotting. Both SCF and anti-IgE were effective drivers of
PGD2 generation from mast cells (n = 20). Indomethacin
and FR122047 (0.1 lM) completely abrogated (P\ 0.05,
n = 4) the production of PGD2 from lung mast cells acti-
vated by SCF or anti-IgE while celecoxib (0.1 lM) was
ineffective (P[ 0.05, n = 4). None of these COX inhibitors
affected the stimulated generation of either histamine or
leukotrienes. Western blotting studies showed that COX-1
was strongly expressed in all mast cell preparations while the
expression of COX-2 was, at best, weak (n = 4). These
findings indicate that COX-1 is the principal isoform
involved in PGD2 generation from human lung mast cells.
Academic Unit of Respiratory Medicine, The University of
Sheffield, Sheffield S10 2RX, UK. E-mail:
bbaothman1@sheffield.ac.uk
L-ASPARAGINASE-INDUCED ALLERGY IN MICE:
EFFECTS OF CONCOMITANT DRUGS AND ANTI-
IgE ANTIBODY
M. Mio, A. Nogami-Hara, K. Yabuki, K. Suwaki, A. Handa,
A. Shimada
L-Asparaginase (L-Asp) derived from E. coli is one of the
essential drugs for acute lymphoblastic leukemia. Native L-
Asp often causes allergies, including anaphylaxis. At pre-
sent, there is neither suitable therapy for L-Asp allergy nor
alternative L-Asp in Japan. Moreover, there is no suit-
able animal model of L-Asp allergy. In this study, we
induced type I allergy to E. coli L-Asp in mice and the
effect of anti-IgE antibody was evaluated. In addition, we
investigated the effects of concomitant drugs on this model
using methotrexate (MTX) and cyclophosphamide (CY)
which reportedly impair the functions of Th17 and Treg
cells, respectively. Male BALB/c mice (7 week old) were
i.p. injected L-Asp with Al(OH)3 gel on days 0 and 14. The
right ears of the mice were locally sensitized on days 17,
20, 23 by i.d. injection of L-Asp. Antigen challenge was
carried out on day 26 by i.d. injection of L-Asp.
Methotrexate (MTX) and cyclophosphamide (CY) were
i.p. administrated at day –2 and day 12. On day 25, either
anti-IgE Ab or control IgG was i.p. administered to the
sensitized mice. L-Asp challenge immediately induced ear
edema, reaching a peak at 1 h after stimulation, which
subsided within 24 h. Microscopic observations showed
eosoniphil infiltration (H&E staining; 0.5 ± 0.2 cells/HPF
in control ears and 10.4 ± 1.0 cells/HPF in challenged
ears, P\ 0.001, n = 3) and degranulation of mast cells
(toluidine blue staining; 8.4 ± 0.9 % in control ears and
47.6 ± 5.8 % in challenged ear, P\ 0.001, n = 3). Such
changes due to L-Asp challenge were inhibited by pre-
treatment with anti-IgE antibody (BD Bioscience, clone
R35-92, which specifically reacts with mouse IgE of Igh-
C[a] and Igh-C[b] haplotypes). Cyclophosphamide, but not
methotrexate, enhanced L-Asp-induced ear edema. This
augmentation was also inhibited by a pretreatment with
anti-IgE antibody. From these results, it was concluded
that (1) non-anaphylactogenic neutralizing antibody of IgE,
such as omalizumab, can be a candidate drug for the
treatment of L-Asp allergy, and (2) CY-induced suppres-
sion of Treg function may enhance Th2 responses so as to
augment L-Asp allergy. Further investigations for the
detection and avoidance of L-Asp allergy are under the
way.
Laboratory of Pharmacology, Shujitsu University, School
of Pharmacy, Japan. E-mail: mio@shujitsu.ac.jp
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ANTI-INFLAMMATORY EFFECT OF
A COMBINED TREATMENT WITH AN H1R
ANTAGONIST AND AN H4R ANTAGONIST IN
A MOUSE MODEL OF ATOPIC DERMATITIS
K. Rossbach, H. Ko¨chling, K. Schaper, W. Ba¨umer,
M. Kietzmann
Atopic dermatitis (AD) is a chronic relapsing allergic skin
disorder characterized by skin lesions, pruritus and ele-
vated serum levels of allergen specific IgE. In a mouse
model of AD, the ovalbumin (OVA)—induced model, H4R
knockout mice showed a clear amelioration of skin lesions
compared to wild type mice. However, neither H4R
antagonists nor H1R antagonists exhibit distinct anti-in-
flammatory effects in the OVA model. This study was
performed to test the anti-inflammatory potential of a
combined treatment with an H1R antagonist (mepyramine)
and an H4R antagonist (JNJ39758979; JNJ) in the OVA—
induced AD model. Mice were treated systemically during
the challenge phase with a combination of JNJ and
mepyramine (both 20 mg/kg twice daily). AD-like lesions
were induced by repeated epicutaneous application of
OVA. Severity of dermatitis was assessed by standardized
skin score. As an indicator of pruritus, scratching behavior
of mice was determined. Mice were sacrificed after the
second challenge and samples were taken for further
analysis. Mice treated with JNJ and mepyramine showed a
clear amelioration of skin lesions, with a diminished influx
of inflammatory cells and a reduced epidermal hyperpro-
liferation compared to vehicle-treated mice. Scratching
behavior was significantly reduced in mice treated with JNJ
and mepyramine. Moreover, mice had a reduced amount of
OVA-specific IgE in serum and a reduced number of
splenocytes and lymph node cells. The cellular profile in
skin-draining lymph nodes was not modulated. The level of
OVA-induced IL-10 production of splenocytes was sig-
nificantly higher in JNJ and mepyramine treated mice,
whereas IL-4 and IL-6 secretion did not differ between the
groups. Hardly any INF-c was detectable in supernatants of
splenocytes. JNJ and mepyramine-treated mice showed a
reduced inflammatory response compared to vehicle trea-
ted mice. Thus the combined treatment with an H1R and an
H4R antagonist might be a new therapeutic strategy to treat
AD.
Institute for Pharmacology, Toxicology and Pharmacy,
University of Veterinary Medicine, Hannover, Germany.
E-mail: kristine.rossbach@tiho-hannover.de
IMPACT OF HISTAMINE ON TYPE 2 IMMUNE
RESPONSE
K. Schaper, B. Ko¨ther, H. Stark, T. Werfel, R. Gutzmer
Type 2 immune responses are defined by the cytokines
interleukin 4, (IL-4); IL-5, IL-9 and IL-13. While IL-5
serves mainly as stimulator of eosinophils, IL-13 also
regulates cell-mediated immunity and thereby enhances
mucus production and airway hyperreactivity. Allergic
disorders, such as asthma or atopic dermatitis are associ-
ated with increased Th2 cytokines. Th2 cells are known to
be the major source of IL-5 and IL-13, but also other cells
like type 2 innate immune cells produce these cytokines.
However, the role of histamine in the mechanisms of ini-
tiation and control of type 2 responses, especially the effect
on the production of IL-5 and IL-13 is not fully understood.
Therefore our aim was to investigate possible effects of
histamine on IL-5 and IL-13 production of innate lymphoid
cells as well as T helper cells. We therefore isolated
PBMCs from healthy subjects and depleted CD3+ cells.
CD127+ cells were further enriched by means of magnetic
cell separation. On stimulation with IL-2 and IL-25 for
5 days CD3-CD127+ cells produced high amounts of IL-5
and IL-13, while the cytokine production of CD3+ cells
was lower. CD3-CD127- cells and unstimulated CD3-
CD127+ cells did not produce any detectable IL-5 and IL-
13. Incubation of the cells with histamine during the 5 days
of stimulation augmented the production of IL-5 and IL-13
in CD3-CD127+ cells significantly, but not in CD3+ cells.
Thus, our results indicate that histamine foster a Th2 milieu
by directly affecting IL-5 and IL-13 production in innate
lymphoid cells.
Department of Dermatology and Allergy, Hannover Med-
ical School, Carl-Neuberg-Strasse 1, D-30625 Hannover,
Germany. Email: schaper.katrin@mh-hannover.de
MODULATION OF ANTIGEN SPECIFIC T CELL
PROLIFERATION BY HISTAMINE
M. Wohlert, K. Schaper, S. Mommert, H. Stark, T. Werfel,
R. Gutzmer
Dendritic cells (DCs) are potent antigen presenting cells
and are able to induce proliferation of T cells. Both cell
types are found in chronic inflammatory skin diseases. As
histamine is also upregulated in lesions of inflammatory
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skin diseases, we decided to investigate the role of his-
tamine and its receptors on antigen specific T cell
proliferation and interaction of T cells and DCs. There-
fore, human peripheral blood mononuclear cells (PBMCs)
of allergic donors were stimulated with allergens.
According to the sensitization of the donor, Phl.p.5 (Ph-
leum pratense), BetV1 (Betula pendula) or Der p2
(dermatophagoides pteronyssinus) were used at a con-
centration of 2.5 lg/ml. Stimulation was performed in the
absence or presence of histamine or histamine receptor
agonists and T cell proliferation was determined after
5 days using a thymidine incorporation assay. Only
experiments with an increase of T-cell proliferation in
response to allergen stimulation were assessed for the
effect of histamine. In Der p2 stimulated PBMCs, stim-
ulation with histamine and the histamine 4 receptor
agonists 4-methylhistamine and ST1006 decreased T cell
proliferation. This trend was also observed in PBMCs
successfully stimulated with Phl.p.5 and BetV1 although
the number of experiments is currently too low to draw
firm conclusions. To preclude an interfering influence of
endogenous histamine, we examined the supernatants of
cell cultures by means of ELISA. Generally, histamine
levels were below 4 ng/ml and 20 % of samples showed
no detectable histamine with a detection limit of 1.3 ng/
ml. Taken together our first results suggest that allergen
specific T cell proliferation is modulated by the histamine
4 receptor.
Division of Immunodermatology and Allergy Research,
Department of Dermatology and Allergy, Hannover Med-
ical School, Hannover, Germany. E-mail:
wohlert.mareike@mh-hannover.de
CARBONIC ANHYDRASE IX AND
CYCLOOXYGENASE-2 INHIBITORS AS A NEW
CLASS OF ANTI-INFLAMMATORY DRUGS
L. Lucarini, C. Lanzi, M. Durante, E. Bigagli, F. Carta,
C. T. Supuran, E. Masini
The carbonic anhydrase (CA) family includes 16 catalyti-
cally active zinc metallo-enzymes that catalyze the
reversible interconversion of carbon dioxide and water to
bicarbonate and protons. CA inhibitors are a potential new
class of antitumour agents; the selective inhibition of CAIX
decreases tumour cell proliferation and induces apoptosis
in human cancer cells. Moreover, sulfonamide CAIX
inhibitors exhibit anti-inflammatory effects in rats with
permanent middle cerebral artery occlusion. Macrophages
are involved in inflammation, and histamine up-regulates
the production of pro-inflammatory cytokines stimulated
by LPS.
The aim of the present study was to investigate the
pharmacological profile of a new class of drugs (1e, 2e, 3e,
6e), endowed with CAIX and COX inhibition activity.
RAW 264.7 macrophages were incubated for 18 h with
LPS (1 lg/mL) and pre-treated or not with different con-
centrations of the studied drugs (10-7–10-4 M). The
prostaglandin E2 (PGE2) production was quantified with a
commercial ELISA kit. On human platelet-rich plasma
(PRP), the inhibition of platelet aggregation, induced by
10 lMADP after 5’ incubation, was studied, in presence or
absence of the studied compounds. The concentration of
TXA2 was measured as TXB2 production with an ELISA
method on PRP after clotting.
Our results show that macrophages contain significant
amounts of histamine (\0.008 pg/cell). PGE2 production is
lowered in LPS-stimulated RAW 264.7 cells treated with
CAIX/COX inhibitors with a dose–response effect (Vehi-
cle: 287.74 ± 11.3 pg/mL; 1e 10-5 M: 89.28 ± 7.65 pg/
mL; ibuprofen 10-5 M: 116.5 ± 7.81 pg/mL). CAIX/COX
inhibitors do not modify neither the inhibition of platelet
aggregation in comparison with the reference molecules
(baseline: 100 %; 1e 10-4 M: 28.97 %; ibuprofen 10-4 M:
26.71 %), nor the production of TXB2 in comparison with
the reference molecules (baseline: 218.25 ± 3.3 ng/mL; 1e
10-4 M: 100.72 ± 1.5 ng/mL; ibuprofen 10-4 M:
97.32 ± 4.3 ng/mL).
Our findings validate these molecules, endowed with a
double COX-2 and CAIX inhibition, as interesting new
anti-inflammatory drugs for a novel therapeutical approach
to contrast cancer and inflammation.
Department of Neuroscience, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-
ence, Florence, Italy. E-mail: laura.lucarini@unifi.it
EXPERIMENTAL AUTOIMMUNE MYOCARDITIS
(EAM) IN RATS AND THERAPEUTIC H1-H4
RECEPTOR INHIBITION
A. Stasiak, J. Gola, K. Kraszewska, M. Mussur,
U. Mazurek, H. Stark, W. A. Fogel
Histamine plays an important role in immune and inflam-
matory responses. Produced by various cells and
interacting with four G protein-coupled receptors, H1-H4, it
can evoke different effects. Using rat model of autoimmune
myocarditis, we investigated whether EAM progression
could be influenced by chronic modulation of histamine
receptor signalling. EAM was induced in male Lewis rats
by immunization with porcine heart myosin in complete
Freund’s adjuvant (0.33 mg/each rear footpad), twice with
one week apart. Compounds were applied daily for the first
2 weeks: for H1R-Mepyramine (i.g. 20 mg/kg); H2R-
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Ranitidine (s.c.10 mg/kg); H3R-Ciproxifan (s.c. 1 mg/kg),
H4R-ST 994 (antagonist), ST1012 (inverse agonist) (each
by Alzet osmotic pump, 1 mg/kg). Quinapril (i.g. 20 mg/
kg) was used as a reference drug. Echocardiographic
examination was done before, and at 2 and 3 weeks of
EAM. Plasma ceruloplasmin was used as an inflammation
marker. Four weeks post myosin, all survivors were sac-
rificed by decapitation. Blood was collected from neck
arteries, the hearts were excised, macroscopically evalu-
ated and their weights recorded. The left and right atria and
ventricles were dissected and immediately frozen on dry
ice, heart apexes put into formalin for histology. The tis-
sues were processed to measure hydroxyproline
(spectrophotometry), histamine (ELISA) and transcripts for
MCP-1 and TNFa (RT-PCR). Cardiac hypertrophy was
seen in all EAM rats, however, it was lowest for ST994
treated ones. The means for heart weight to body weight
ratio ranged from 0.62 to 0.99 % vs 0.30 % for intact rats.
The % decreased fractional shortening, FS = 12.8 ± 2.87
and left ventricular ejection fraction LVEF % 31.6 ± 6.31
show significant decrease in cardiac function by EAM
progression. Both these parameters were higher in rats
treated with histamine receptor antagonists, especially
Mepyramine. However, left ventricle (LV) from
Mepyramine-treated EAM rats had more copies of TNFa
mRNA and MCP1 mRNA than LV from EAM rats,
although the levels of both transcripts were the highest in
LV of EAM-Ranitidine rats. Four weeks post EAM
induction LV expressed a high degree of fibrosis, hydrox-
yproline concentration being 2–5 fold of control level.
Histamine concentrations in LV were inversely correlated
to hydroxyproline. All antihistaminics used, except ST1012
inverse agonist, efficiently reduced myocardial fibrosis as
evidenced by LVED/S d, which was 0.03 cm for EAM vs
0.08 cm for ST 1012 while 0.12–0.19 cm for other receptor
ligands. ST 994 inhibited inflammatory process at early
stage (inflammatory cell infiltration) as indicated by
unchanged LVEF and FS: 61 vs 67 % and 31 vs 32 %,
respectively, for EAM + ST994 vs intact rats. There were
great individual differences in disease progress and mor-
tality, despite use of an inbred rat strain. The lowest
mortality was seen in the EAM + ST994 group suggesting
a novel use for H4R-antagonists. This work was supported
by the Grant No 2012/04/M/NZ4/00212 from National
Science Centre, Cracov, Poland.
Department of Hormone Biochemistry, Medical University
of Lodz, Poland. E-mail: wieslawa.agnieszka.fogel@
umed.lodz.pl
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THE ROLE OF HISTAMINE IN THE MEMORY OF
EMOTIONALLY-SALIENT EXPERIENCES
P. Blandina
Phobias, panic attacks and PTSD are extremely common.
Sitting at the heart of much fear is emotional memory—all
the associations that one has between various stimuli and
experiences and his emotional response to them. Memory
is a multi-state process that includes acquisition, consoli-
dation and retrieval. We report that the integrity of the
brain histaminergic system is necessary for consolidation
of long- term memory (LTM) of step-down inhibitory
avoidance (IA), a task that explores emotional memory in
animals. Histamine depletion impairs IA-LTM, and his-
tamine infusion into in hippocampus or basolateral
amygdala (BLA) restores LTM in histamine-depleted rats.
The restoring effect in BLA occurs even when hippocam-
pal activity was impaired. Cyclic adenosine
monophosphate responsive-element-binding protein
(CREB) phosphorylation correlates anatomically and tem-
porally with histamine-induced memory recall. Thus,
histamine neurotransmission appears critical to provide the
brain with the plasticity necessary for IA memory through
recruitment of alternative circuits that provide compen-
satory plasticity when one brain structure is compromised.
We report that cerebral histamine depletion impairs also
retrieval of IA in rats, and blunts retrieval-induced c-Fos
activation and CREB phosphorylation in the hippocampus.
Histamine infusion into the hippocampus restores IA
retrieval in histamine-depleted rats by targeting brain
H1 receptors. Our study uncovers previously unidentified
mechanisms involved in memory retrieval, and offers tar-
gets for developing novel pharmacotherapies to treat
dysfunctional aversive memories, as well as to improve the
efficacy of exposure psychotherapies. Memory determines
the uniqueness of our personal history, and is decisive for
each individual to survive and prosper. However, irrational
fear is no longer useful and life-saving, and drugs
decreasing painful emotional memories can help to get rid
of pathological anxiety.
Department of Neurosciences, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-




The effect on memory consolidation of intracerebral
microinfusions of histamine, its various H1, H2 and H3
receptor agonists and antagonists and the histamine
enhancer, SKF 94188 was recently studied in detail in
various papers from our group. Immediate posttraining
histamine given into the basolateral amygdala or the CA1
region of the hippocampus enhances memory consolidation
of one-trial inhibitory avoidance in rats through H2 and H3
receptors respectively. Both effects are parallel and inde-
pendent. In addition, it also enhances consolidation of the
extinction of this task acting through H2 receptors in hip-
pocampus. Posttraining histamine also induces memory
facilitation in the object recognition task, acting through
both H1 and H2 receptors in hippocampal CA1 where,
however, H3 receptors have a depressant modulatory effect.
The overall effect of histamine in this task is therefore
complex. However, the findings show that histamine reg-
ulation is not limited to the memory consolidation of fear-
or fear-related memories but is exerted also on that of more
purely cognitive tasks. Interestingly, histamine acting
through H2 receptors in hippocampal CA1 reverses the
deleterious effect of the exposure of rats to partial postnatal
maternal deprivation on their memory consolidation of
inhibitory avoidance when they reach adult age. This effect
is shared by the cholinergic agents, donepezil and galan-
tamine given orally and/or by physical exercise during
young adulthood, suggesting that the chronic cognitive
impairment caused by early maternal deprivation is a
multifactorial phenomenon. This work was supported by
the National Research Council of Brazil.
Centro de Memoria, Pontifical Catholic University, Porto
Alegre, Brazil. E-mail: ivone.izquierdo@terra.com.br
BRAIN HISTAMINE MODULATES INHIBITORY-
AVOIDANCE MEMORY RECALL BY
ACTIVATING H1 RECEPTORS IN HIPPOCAMPAL
CA1
R. Fabbri, C. R. G. Furini, M. B. Passani, G. Provensi,
E. Baldi, C. Bucherelli, I. Izquierdo,
J. de Carvalho Myskiw, P. Blandina
Memory includes acquisition, consolidation and recall.
Retrieval is the only measure of memory but little is known
about its mechanisms. Histaminergic neurons are located in
the tuberomamillary nucleus, send projections to the whole
brain and regulate different types of memory. Here we
study the involvement of brain histamine (HA) in inhibi-
tory avoidance (IA) memory retrieval, which brain areas
are involved, which HA receptor mediates HA action and
the biochemical substrates required. Wistar male rats
(3 months old; 300–330 g; 8–12 animals for each experi-
mental group in inhibitory avoidance task and 4–5 animals
for c-Fos protein immunostaining and Western-Blot
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analysis of p-CREB) were implanted with cannulas in the
lateral ventricle (LV), hippocampal CA1, basolateral
amygdala (BLA) or ventromedial prefrontal cortex
(vmpfCX). 24 h before or after inhibitory avoidance (IA)-
training, when animals received a 2-s 0.5-mA scrambled
foot shock, rats were infused i.c.v. with a-fluoromethyl-
histidine (a blocker of histidine decarboxylase; a-FMH) or
saline. 48 h after training rats underwent IA-retention test,
and step-down latencies were evaluated. a-FMH rendered
rats amnesic, independently of the time of infusion as
shown by step-down latencies significantly shorter than
those of controls. Application 10 min before the retention
test of HA in CA1 of rats that had received a-FMH 24 h
after training restored IA memory. HA was ineffective
when given in the BLA or the vmpfCX. Intra-CA1 injec-
tions of a selective H1 receptor agonists, but not of an H2
agonist reinstated IA memory. The H1 receptor antagonist
pyrilamine disrupted IA memory retrieval in normal rats,
thus suggesting a role of endogenous HA in IA memory
retrieval. Neurochemical analysis showed that c-Fos
immunopositive neurons were significantly less in the CA1
of 24 h after training a-FMH-treated rats, hence amnesic,
compared with controls with normal IA memory. We found
also reduced levels of pCREB, a crucial player in memory,
in the CA1 24 h after training a-FMH-treated rats com-
pared to controls. Targeting the histaminergic system
modifies emotional memory retrieval, hence HA ligands
may reduce dysfunctional aversive memories and improve
the efficacy of exposure psychotherapies.
The presenter of this abstract was the winner of the
Young Investigator Award (2016).
Dept of Neurosciences, Psychology, Drug Research and
Child Health (NEUROFARBA), University of Florence,
Florence, Italy. E-mail: roby.fabbri11@gmail.com
HISTAMINE H1 RECEPTOR OCCUPANCY IN
HUMAN BRAIN MEASURED BY POSITRON
EMISSION TOMOGRAPHY
K. Yanai, N. Okamura, M. Tashiro, T. Yoshikawa
Histamine is considered a ‘‘bad guy’’ from an allergy point
of view. However, histamine is functioning as a ‘‘good guy’’
in several other physiological aspects. In particular, his-
taminergic neurons form one of the most important neuronal
systems that maintain and stimulate wakefulness. Histamine
also functions as a bioprotector against various noxious and
undesirable stimuli, for example, convulsion, nociception,
drug sensitization, ischemic lesions, and stress. It may also
be suggested that the activation of histaminergic neurons is
important to maintain mental health. The guideline for
allergic diseases, such as pollenosis and atopic dermatitis,
recommends non-sedating antihistamines with low central
nervous system (CNS) penetration to avoid suppressing
histamine’s CNS actions. Positron emission tomography
(PET) is often used to evaluate the efficacy of CNS drugs by
determining the drugs’ neuronal receptor occupancy rate.
While the blood concentration levels of a drug are frequently
determined clinically, i.e., via therapeutic drug monitoring
(TDM), CNS drugs do not necessarily show a correlation
between their blood concentration levels and effect. We
have reported on brain H1 receptor occupancy measure-
ments of antihistamines, antidepressants, and
antipsychotics. The clinically most important contribution
of PET studies on histamine H1 occupancy in the brain of
antihistamine-treated allergic patients is probably to the
identification of the narrow therapeutic window of less than
20 %of systemic and topical treatments that permits optimal
treatment without causing significant sedative side effects.
Thus, these PET results may be useful for the development
of optimal antihistamine dosing strategies. In the present
review, the results of our previous studies on the significance
of brain histamine H1 receptor occupancy in human brain
were summarized from the perspective of histamine func-
tion in the CNS.
Department of Pharmacology, Tohoku University School of
Medicine, Senday, Japan. Email: yanai@med.tohoku.ac.jp
MEDIATORS OF INFLAMMATION IN THE
ANTINOCICEPTIVE ACTION OF JNJ7777120 IN
RATS
P. Rzodkiewicz, E. Ga˛sin´ska, D. Ła_zewska,
K. Kiec´-Kononowicz, M. Bujalska-Zadro_zny,
S. Mas´lin´ski
Importance of histamine H4 receptor in pain and mecha-
nisms of action of its ligands are unknown. Its activity may
be primary related to the anti-inflammatory effect. We
analyzed antinociceptive and antinflammatory action of
JNJ7777120 (J77) (25 mg/kg—i.p.) its interactions with
COX and LOX inhibitors in acute nociception (AP), car-
rageenan-induced inflammation (CII) and adjuvant-induced
arthritis (AIA) in LEW/CriCmed male rats (n = 7/group).
Mann–Whitney U test was used to identify differences
among groups with p\ 0.05. Nociceptive thresholds
(Randall-Sellito, Tail flick, Plantar test), edema, blood
count, histamine, prostaglandin E2 metabolite (PGEM) and
LTB4 levels in plasma, levels of MCP-1 in plasma and
cerebrospinal fluid (CSF) and chemiluminescence of
leukocytes were analyzed. In AP, J77 increased mechanical
and thermal threshold and decreased concentration of
MCP-1 in CSF and plasma. Indomethacin (3 mg/kg—i.p.)
and celecoxib (3 mg/kg— i.p.) reduced J77 impact on the
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MCP-1 level. Celecoxib decreased J77 activity towards
mechanical but potentiated towards thermal stimulus. In
CII, J77 reduced mechanical hyperantinociception, plasma
concentration of LTB4 and chemiluminescence. Adminis-
tration of celecoxib with J77 potentiated antinociception
and reduced level of PGEM. Co-administration of esculetin
(10 mg/kg—i.p.) and J77 decreased chemiluminescence. In
AIA, J77 reduced mechanical hyperantinociception,
edema, percentage of neutrophils, levels of MCP-1 and
chemiluminescence. Co-administration of indomethacin
and J77 reduced PGEM, MCP-1, and induced chemilumi-
nescence levels. Celecoxib administered with J77
decreased PGEM and MCP-1 levels. Esculetin completely
abolished the J77 antinociceptive effect produced. The
antinociceptive effect of J77 in rat models of inflammatory
nociception is in part secondary to its anti-inflammatory
action but both periphery and central mechanisms are
involved. Histamine receptor H4 ligands interact with
common NSAID and so may influence therapy and so this
should be examined in more detail. This project was
financed by a grant from the National Science Center
based on decision No DEC-2011/03/N/NZ4/03765.
Department of Biochemistry and Molecular Biology,
National Institute of Geriatrics, Rheumatology and Reha-
bilitation, Warsaw, Poland. E-mail: przemyslaw@
rzodkiewicz.eu
CHARACTERIZATION OF HISTAMINE H1
RECEPTOR EXPRESSION IN RAT EMBRYO
CORTICAL AND MESENCEPHALIC
NEUROEPITHELIA: IN THE SEARCH FOR ITS
FUNCTIONAL ROLE DURING FETAL
NEUROGENESIS IN VIVO
B. Ma´rquez-Valadez, F. Dı´az, J.-A. Arias-Montan˜o,
A. Molina-Herna´ndez
The histamine H1 receptor (H1R) is expressed in the rat
neural tube from embryo day 14 (E14) to E20. Histamine
reaches its highest level during the neurogenic peak (E14)
and has been shown to participate in neuronal differentia-
tion through H1R activation in vivo and in vitro, affecting
in a contrasting manner cortical and ventral mesencephalic
neuroepithelia neural stem cells. In the cerebral cortex,
histamine increases FOXP2 neuron phenotype, a cortical
deep layer phenotype implicated in speech in humans,
ultrasonic sound generation in rodents and movement
coordination. In ventral mesencephalic neural stem cells
histamine promotes neuronal differentiation, but at high
concentrations reduces the tyrosine hydroxylase phenotype
in vivo and in vitro. Because histamine has been proposed
to participate in neuronal commitment and the main cell
population at E12 is neural stem cells, it is important to
determine where in the cortical and ventral mesencephalic
neuroepithelia the expression of H1Rs, their cellular
localization and the cell population that expresses the
receptor. IR rat embryos of 12- and 14-day old were used to
study the H1R expression by RT-PCR, its membranal
localization by binding assays. Additionally evidence of
the presence of its protein in neural stem cells using double
immunohistochemistry was studied to detect the H1R and
nestin which is a marker of neural stem cells. Our results
showed H1R expression in both neuroepithelia at E12 and
E14, its presence in total forebrain/midbrain membranes
with a higher density at E12 and co-localization with
nestin. In conclusion, the H1R is expressed by neural stem
cells in the cortical and ventral mesencephalic neuroep-
ithelia with a likely membranal localization, suggesting a
functional role in cortical and mesencephalic development,
a hypothesis that we have begun to study by blocking the
effect of endogenous histamine at H1Rs in 12 day-old rat
embryos.
Departamento de Biologı´a Celular, Instituto Nacional de
Perinatologı´a, Ciudad de Me´xico, Me´xico. E-mail:
minab_us@yahoo.com
DOPAMINERGIC REGULATION OF HISTAMINE
NEURONS IN ZEBRAFISH
P. Panula, Y.-C. Chen
The brain histaminergic system is altered in diseases which
affect the dopamine system. For example, levels of his-
tamine and the density of histaminergic nerve fibers are
increased in brains of Parkinson’s disease patients. Trans-
lation inhibition of the second tyrosine hydroxylase (th2) in
zebrafish leads to a decrease in dopamine content and an
increased number of histamine neurons in developing
zebrafish. We now sought to identify the mechanisms
involved in this regulation. Treatment of the developing
fish from 1 to 5 days post fertilization with 10 mM
L-DOPA (precursor of dopamine), 10 uM SKF38393
(drd1-like receptor agonist) or 7.5 uM quinpirole (drd2-like
receptor agonist) led to significant declines in the number
of histamine neurons. We then analyzed which of the
dopamine receptors (drd) are located in the posterior
hypothalamus, where the histamine neurons are found.
Dopamine receptors were cloned and the developmental
expression patterns analyzed. Drd1 was heavily expressed
in hindbrain domains and retina, but not in the posterior
hypothalamus. Drd2a was found throughout the brain, but
not particularly strongly in the hypothalamus. Drd2b was
found in the forebrain and hypothalamus, but not promi-
nently in the caudal part. Drd2l was expressed heavily in
S20 The European Histamine Research Society
123
the diencephalon, most prominently in the hypothalamus
and in the cell cluster which contains the histaminergic
neurons. Drd3 was expressed significantly in the forebrain
and also in the hindbrain, whereas expression in the
hypothalamus was modest. Drd4 was expressed most
prominently in the forebrain. The receptor expression
patterns and drug treatment results support the concept that
dopamine regulates the histaminergic neurons, most likely
directly through dopamine receptors expressed in his-
taminergic neurons. Double in situ hybridization
experiments and studies using dopamine receptor knock-
out fish are needed to verify the results. Multiple receptors
could be involved, but the drd2l is the most likely
candidate.
Neuroscience Center and Department of Anatomy,
University of Helsinki, Helsinki, Finland. E-mail:
pertti.panula@helsinki.fi
LACK OF ANTIDEPRESSANT-LIKE EFFECT OF
OLEOYLETHANOLAMIDE IN HISTAMINE-
DEFICIENT MICE PARALLELS REDUCED
HIPPOCAMPAL AND CORTICAL CREB
PHOSPHORYLATION
A. Costa, L. D. C. Mannelli, C. Ghelardini, P. Blandina,
M. B. Passani, G. Provensi
The failure of patients to respond to antidepressant drug
therapy reveals the need to investigate alternative strategies
and treatments for depression. Preclinical studies demon-
strated that the endogenous agonist of Peroxisome
Proliferator Activated Receptor-alpha (PPAR-a), Oleoy-
lethanolamide (OEA) exerts an antidepressant-like effect.
We previously have observed that neuronal histamine (HA)
participates to OEA-induced central effects. Thus, we
investigated if brain HA is also required for OEA-induced
antidepressant-like effect in mice using the Tail Suspension
Test (TST), a classical behavioural paradigm of antide-
pressant-like activity. Thus, mice unable to synthesize HA
due to disruption of the histidine decarboxylase gene
(HDC-KO) or to 5 lg i.c.v. injection of alpha-fluo-
romethylhistidine, a suicide inhibitor of this enzyme, were
treated with OEA or vehicle. Results were compared to
wild type (WT), and saline i.c.v. injected controls. In the
TST, OEA (5 or 10 mg/kg i.p.; n = 5–12) significantly
reduced immobility time in WT and control mice
(P\ 0.001); this effect was not observed in HA deficient
mice. Imipramine (10 mg/kg i.p; n = 5–10) reduced
immobility time of HA-deprived mice as well (P\ 0.001).
Neurochemical responses were studied by evaluating the
phosphorylation level of cyclic AMP-response element
binding protein (pCREB), a major player in the molecular
mechanisms of antidepressant treatments. In normal mice
but not in HA-deficient mice, OEA (10 mg/kg i.p.; n = 5
per experimental group) increased significantly cortical
(p\ 0.05) and hippocampal (p\ 0.01) pCREB. As
observed in behavioural responses, imipramine (10 mg/kg
i.p.; n = 5) increased CREB phosphorylation indepen-
dently of the presence of HA (p\ 0.05). Hence, the
neurochemical results parallel the behavioural data. We
therefore suggest that OEA requires the integrity of the
brain HA system to exert its antidepressant-like effects.
Department of Neuroscience, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-
ence, Florence Italy. E-amil: alessia.costa@unifi.it
THE ROLE OF HISTAMINE RECEPTORS IN THE
CONSOLIDATION OF OBJECT RECOGNITION
MEMORY
C .R. G. Furini, C. K. B da Silveira, F. Benetti,
S. da C. Monteiro, I. Izquierdo
Findings have shown that histaminergic system is involved
on the consolidation, reconsolidation and extinction of
different memories. Here we investigated in the CA1
region of the hippocampus the role of the histaminergic
system on the consolidation of object recognition (OR)
memory. For this, male Wistar rats (3 months; 300–330 g)
with infusion cannulae stereotaxically implanted in the
CA1 region of the dorsal hippocampus were trained in an
OR task in the presence of two different objects (A and B).
Twenty-four hours later, the animals were submitted to a
test phase in the presence of a familiar and a new object (A
and C). The training and test phase each lasted 5 min,
during which the time that the animals spent exploring
(sniffing and touching) the objects was recorded. The
compounds to be tested were bilaterally infused into the
CA1 region (1 ll/side) immediately, 30, 120 or 360 min
after training. The infusion of vehicle or the H1-receptor
agonist, pyridylethylamine (10 mM), the H2-receptor ago-
nist, dimaprit (10 mM) and the H3-receptor antagonist,
thioperamide (50 mM), immediately, 30, 120, or 360 min
did not affect the consolidation of the OR memory. How-
ever, the infusion of the H1-receptor antagonist, pyrilamine
(50 mM), the H2-receptor antagonist, ranitidine (50 mM)
and H3-receptor agonist, imetit (10 mM), at 30 and
120 min after training impaired the consolidation of OR
memory but not immediately or at 360 min. A similar
result was observed after the infusion of the H1-receptor
antagonist, the H2-receptor antagonist and the H3-receptor
agonist immediately and at 360 min after training. There-
fore we have shown that OR memory was impaired by
posttraining blockade of H1 and H2-receptors or by the
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activation of H3-receptors 30 and 120 min posttraining, that
is, in a period when hippocampal memory consolidation
takes place. This suggests that the histaminergic system
participates in the consolidation of object recognition
memory through the H1, H2, and H3 receptors.
Memory Center, Brain Institute of Rio Grande do Sul,
Pontifical Catholic University of Rio Grande do Sul, Porto
Alegre, Brazil. E-mail: cristianefurini@hotmail.com
MODULATION OF THE CONSOLIDATION OF
SOCIAL RECOGNITION MEMORY IN TWO
DISTINCT BRAIN AREAS
C. Garrido Zinn, N. Clairis, L. Cavalcante, C. R. G. Furini,
I. Izquierdo, J. de Carvalho Myskiw
Social recognition memory (SRM) is the ability to dis-
criminate between familiar and unfamiliar conspecifics
and is essential for social interaction, adaptive social
behaviour, reproduction and survival. Here we investigate
the involvement of H2 histamine, b-adrenergic and D1/D5
dopamine receptors in the CA1 region of the hippocampus
and in the basolateral amygdala (BLA) on the consolida-
tion of SRM. For this, adult male Wistar rats (3 months
old) with infusion cannulae implanted in the CA1 or in the
BLA were subjected to a social discrimination task. The
adults were habituated (20 min/day, for 4 consecutive
days) to the experimental apparatus (open field arena) and
24 h after the last habituation session were exposed to a
juvenile (male Wistar rats; 21 days old) for 1 h (sample
phase). Twenty-four hours later, adults were subjected to a
5-min retention test in the presence of the previously
presented juvenile (familiar) and a second juvenile (novel).
The microinjections occurred immediately after the sample
phase. Adults that received infusion of the vehicle (saline
0.9 %), the H2 histamine receptor agonist dimaprit (Dima,
2.34 lg/side), the b-adrenoceptor antagonist timolol (Tim,
1.0 lg/side) or the D1/D5 dopamine receptors agonist
SKF38393 (SKF, 12.5 lg/side) intra-CA1 or Dima, the b-
adrenoceptor agonist isoproterenol (Iso, 10.0 lg/side) or
the D1/D5 dopamine receptors antagonist SCH23390
(SCH, 1.50 lg/side) intra-BLA were able to recognize de
familiar juvenile during the retention test. While adults
that received infusion of the H2 histamine receptor
antagonist ranitidine (Rani, 17.54 lg/side), Iso or SCH
intra-CA1 or Rani, Tim or SKF intra-BLA were not able to
recognize the familiar juvenile during the retention test.
This impairment to recognize the familiar juvenile was
abolished by the co-infusion of Tim plus Iso, Rani plus
Dima or SCH plus SKF into the CA1 or into the BLA.
These results suggest that SRM is modulated by various
systems in different ways.
Memory Center, Brain Institute of Rio Grande do Sul,
Pontifical Catholic University of Rio Grande do Sul
(PUCRS), Porto Alegre, Brazil. E-mail:
jociane_carvalho@hotmail.com
HISTAMINE H3R EXPRESSION CHANGES IN
AMYLOIDOPATHY AND MOUSE MODELS OF
DEMENTIA
P. L. Chazot, N. Lethbridge
Recent studies in Alzheimer’s Disease mouse models and
human cases, using ligand autoradiographical approaches,
suggest that H3R expression is largely unaltered or raised
in some brain structures with age and disease progression.
In this present study, we utilised our pan cross-species anti-
H3R and anti-rH3A/C antibodies both validated for selec-
tivity by H3R KO mice (C57BL background strain) using
various immunobiochemical techniques. We investigated
the time-course (3, 7, 12, 19 months) of H3R expression in
two distinct models of dementia, CD-1 mice and TASTPM
APP/PS double mutant mice. These antibodies labelled
three major H3R isoform monomeric protein species (Mr
40,000, 43,000, 45,000, respectively) (n = 4 samples).
Two-way ANOVA with post hoc test was used to assess
statistical significance (p\ 0.05 was deemed significant)
Based on quantitative immunoblotting, using beta-actin as
standard, we confirmed H3R expression was largely unal-
tered in CD-1 mice in a range of brain structures between
the ages 3 and 12 months; previously shown by our group,
the latter age-point is where CD-1 mice display significant
memory performance deficits. However, an apparent
upregulation of H3Rs appears to occur at the interim
7 month age point in both the cerebral cortex and hip-
pocampus. This expression profile was not capitulated by
the TASTPM mice where no significant differences were
seen between 3 and 7 months of age, but a clear reduction
was seen between 7 and 12 months of age; there is already
significant amyloid load and memory deficits in the
TASTPM model at the 7 month age point, which pro-
gressively worsens thereafter (n = 3–4 replicate animals).
The maintenance or increase in H3R expression seen may
be the result of different compensatory mechanisms
occurring in these two models; CD-1 mice do not display
any detectable amyloidopathy up to at least 12 months of
age, but has clear memory deficits at this age. Between 12
and 19 months of age, there appears to be a profound
decrease in H3R expression in both CD-1 and TASTPM
mice. Both are likely to display, although not proven,
profound memory deficits over this later age range. The
Histamine H3R is preserved or raised in the early stages of
dementia providing a target for therapeutic intervention.
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School of Biological & Biomedical Sciences, Durham
University, Durham, UK. E-mail: paul.chazot@
durham.ac.uk
METHYLPHENIDATE FACILITATES
EXTINCTION LEARNING THROUGH b-
NORADRENERGIC AND D1/D5-DOPAMINE
RECEPTORS
C. R. G. Furini, L. D. Pereira, J. A. Behling, C. G. Zinn,
M. L. Zanini, I. Izquierdo, J. de Carvalho Myskiw
Methylphenidate (MPH), a dopamine and norepinephrine
transporters inhibitor is the first-choice medication for
attention-deficit/hyperactivity disorder. However, the
mechanism(s) of action by which acute administration of
MPH affects learning and memory is poorly understood.
Here we investigated the effect of MPH in the CA1 region
of the hippocampus on extinction learning. Male Wistar rats
(3 months old; 330 g) with infusion cannulae stereotaxically
implanted in the CA1 region were trained in a contextual
fear conditioning (CFC) task, using 3 electrical foot shocks
(0.5 mA, 2 s). Twenty-four hours later, animals were sub-
mitted to a 10-min extinction training (Ext Tr) of CFC, with
the absence of the foot shock. After another 24 h, animals
were placed again in the same apparatus for a 3-min
extinction retention test (Ext Test). Animals that received
intra-CA1 infusion of MPH (12.5 lg/side) 20 min before
the Ext Tr expressed less freezing behavior than Veh-treated
animals during both Ext Tr and Ext Test. Additionally, we
investigated the involvement of b-adrenergic and D1/D5
dopaminergic receptors in this facilitatory effect on extinc-
tion learning induced by MPH. The administration of
MPH + Timolol (1 lg/side; b-adrenergic antagonist) or
MPH + SCH23390 (1.5 lg/side; D1/D5 dopaminergic
antagonist) intra-CA1 20 min before the Ext Tr blocked the
enhancing effect of the MPH on extinction learning.
Whereas Timolol and SCH23390 infused intra-CA1 before
the Ext Tr induced a decrease in freezing behavior in the Ext
Tr and Ext Test compared to Veh group. These results
suggest that MPH in the CA1 region of the hippocampus is
able to facilitate extinction learning and this facilitatory
effect occurs through both b-adrenergic and D1/D5
dopaminergic receptors.
Memory Center, Brain Institute of Rio Grande do Sul,
Pontifical Catholic University of Rio Grande do Sul, Porto
Alegre, Brazil. E-mail: cristianefurini@hotmail.com
THE RELATIONSHIP BETWEEN PROTEIN
SYNTHESIS AND PROTEIN DEGRADATION IN
OBJECT RECOGNITION MEMORY
C. R. G. Furini, J. de C. Myskiw, B. E. Schmidt, C. G. Zinn,
P. B. Peixoto, L. D. Pereira, I. Izquierdo
For decades there has been a consensus that de novo pro-
tein synthesis is necessary for long-term memory. A second
round of protein synthesis has been described for both
extinction and reconsolidation. Recently, it was demon-
strated that consolidation and reconsolidation depend not
only on protein synthesis but also on protein degradation
by the ubiquitin–proteasome system (UPS), a major
mechanism responsible for protein turnover. However, the
involvement of UPS on consolidation and reconsolidation
of object recognition (OR) memory remains unclear. Here
we investigated, in the CA1 region of the dorsal hip-
pocampus, the involvement of UPS-mediated protein
degradation in consolidation and reconsolidation of OR
memory. For this purpose, male Wistar rats (3 months;
330 g) with infusion cannulae stereotaxically implanted in
the CA1 region of the dorsal hippocampus were exposed to
two different stimulus objects (A and B; sample phase).
Twenty-four hours later, the animals were submitted to a
reactivation phase in the presence of a familiar and a new
object (A and C). Twenty-four hours later, they were
subjected to a retention test with different combinations of
objects (A and D; C and D; B and D). The sample, reac-
tivation and test phase lasted 5 min each, during which was
recorded the time that the animals spent exploring the
objects. The microinjections into CA1 were carried out
immediately after the reactivation phase. The UPS inhi-
bitor b-Lactacystin (200 nmol/side) did not affect the
consolidation and the reconsolidation of OR memory,
while the protein synthesis inhibitor anisomycin
(375 nmol/side) impaired the consolidation and the
reconsolidation of the OR memory. However, b-Lacta-
cystin was able to reverse the impairment caused by
anisomycin on the reconsolidation process in the CA1
region of the hippocampus. Therefore, it is possible to
postulate a direct link between protein degradation and
protein synthesis during the reconsolidation of the object
recognition memory.
Memory Center, Brain Institute of Rio Grande do Sul,
Pontifical Catholic University of Rio Grande do Sul, Porto
Alegre, Brazil. E-mail: cristianefurini@hotmail.com
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THE IMPAIRMENT OF AVERSIVE MEMORY OF
RATS SUBMITTED TO NEONATAL MATERNAL
DEPRIVATION WAS REVERTED BY HISTAMINE
ACTING ON THE BASOLATERAL AMYGDALA
F. Benetti, C. Kras da Silveira, J. Rosa, I. Izquierdo
Recent findings suggest a role of brain histamine in the regu-
lation of memory consolidation, particularly in one-trial
inhibitory avoidance (IA) learning and that disruption in the
mother infant relationship i.e. maternal deprivation induces
cognitive deficits. We investigated whether histamine itself,
and histaminergic compounds given into the basolateral
amygdala (BLA) immediately post-training can affect reten-
tion (24 h after training) of one-trial (IA) in rats submitted to
early postnatal maternal deprivation. In all cases, deprived
(Dep) animals (n = 9–12) had lower retention scores than
non-deprived (N-dep) here considered controls group
(n = 10–13). Histamine (10 nmol/0.5 ll/side) induced
memory enhancement on its own in N-dep animals (p\0.01)
and was able to overcome the deleterious effect of Dep
(p\ 0001). The effect of SKF-91488 (50 nmol/0.5 ll/side) is
similar to histamine (p\ 0.0001) for both N-Dep and DEP
rats. The H3 agonist, imetit (10 nmol/0.5 ll/side) mimicked
the enhancing effects of histamine (p\0.0001); neither
agonistH1pyridylethylamine (50 nmol/0.5 ll/side) nor theH2
dimaprit (10 nmol/0.5 ll/side) had any effect. Ranitidine and
thioperamide (50 nmol/0.5 ll/side) co-infusedwith histamine
(10 nmol) fully blocked the restorative effect of histamine on
retention in Dep animals (p\0.01). Thioperamide, in addi-
tion, blocked the enhancing effect of histamine on memory of
the N-dep animals (p\0.001). None of the substances used
when given into BLA had any effect on open-field or elevated
plus-maze behavior in N-dep or Dep rats. Our results were
represent median (±interquartile range) of step-down laten-
cies during a memory retention test carried out 24 h after
training, (n = number of animals per group). ***p\ 0.001
and *p\ 0.5, Saline vs. all treatment (one-way analysis of
variance-ANOVA) in a non-parametric Kruskall–Wallis test
followed by Dunn’s multiple comparison test. These results
suggest that the memory deficit induced by early postnatal
maternal deprivation in rats may at least in part be due to an
impairment of histamine H3 receptor-mediated mediated
mechanisms in the BLA. Our results are limited to experi-
mental design in rats. These results shown the effective action
of histamine inducing cognitive improvement or recover of
fear memory. The extrapolation to humans requires further
experiments, but is an interesting time-window to understand
the receptor binding action and a possibly applicability in
humans for treatment of posttraumatic stress disorder.
Instituto de Cieˆncias Basicas e da Sau´de (ICBS), Departa-
mento de Fisiologia, Universidade Federal do Rio Grande do
Sul, Porto Alegre, Brazil. E-mail: fernando.benetti@ufrgs.br
HISTAMINERGIC MODULATION OF NOVELTY-
INDUCED EXPLORATORY ACTIVITY
S. Abdurakhmanova, S. Rozov, P. Panula
Histamine (HA) is a neurotransmitter released in many
brain regions including cortex, hippocampus, septum and
amygdala. Along with the other aminergic nuclei, tubero-
mamillary histaminergic neurons regulate a variety of
functions such as arousal and vigilance, homeostatic and
cognitive functions. In the current study we analyzed
horizontal and vertical locomotor activity of naı¨ve male
and female histidine decarboxylase knock out (HDC KO)
mice in a novel environment. Animals were tested for 1 h
for 3 consecutive days. HDC-deficient mice showed
decreased exploratory rearings while female HDC KO
mice also moved less than control mice. In contrast to
previous studies the level of anxiety was not increased in
KO mice. The habituation to the novel environment was
also unaltered in HDC KO animals. In the next experiment
we injected saline or amphetamine (AMPH, 5 mg/kg, salt)
i.p. to HDC WT and KO male mice then exposed them to
novel environment, tracked with Ethovision and video-
taped behavior for 30 min. Locomotor activity (LA) was
analyzed with Ethovision software and behavior quantified
manually from video recordings. Trunk blood and brains
were collected after the test. LA and behavioral pattern
were similar in saline treated HDC WT and KO mice.
Blood corticosterone level measured by HPLC was also
unaltered in HDC KO mice. Injection of AMPH 5 mg/
kg switched novelty-induced exploratory activity to per-
sistent locomotion in control mice, while it induced
stereotypy in HDC KO mice. An increasing body of evi-
dence suggests an important role of HA in regulation of
dopamine neurotransmission and thus LA, motivation and
reward. One possible mechanism of histaminergic modu-
lation of novelty-induced behavioral response is
modulation of dopamine release via striatal histamine 3
receptors. Another possible way of exploratory behavior
modulation is via interaction with other aminergic nuclei,
e.g. the basal forebrain acetylcholine system.
Institute of Biomedicine/Anatomy and Neuroscience Cen-
ter, University of Helsinki, Helsinki, Finland. E-mail:
sham.abdurakhmanova@helsinki.fi
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EXTINCTION LEARNING, WHICH CONSISTS OF
THE INHIBITION OF RETRIEVAL, CAN BE
LEARNED WITHOUT RETRIEVAL
J. de Carvalho Myskiw, C. R. G. Furini, B. Schmidt,
F. Ferreira, I. Izquierdo
In the present study, we tested the hypothesis that extinc-
tion is not a consequence of retrieval in unreinforced
conditioned stimulus (CS) presentation but the mere per-
ception of the CS in the absence of a conditioned response.
To test this hypothesis, male Wistar rats (3 months old,
330 g) with bilateral infusion cannulae implanted in the
CA1 region of the hippocampus were trained in a contex-
tual fear conditioning (CFC) task, using two electrical foot
shocks (0.5 mA, 2 s). After 24 h, animals were subjected
to a 20-min extinction training session (Ext Tr) of CFC, in
the same conditioning chamber, without foot shocks.
Twenty-four hours later, animals were subjected to a 3-min
extinction retention test (Ext Test). In all sessions, the
percentage of the time that animals spent freezing (no
visible movement except for respiration) were measured.
Animals that received intra-CA1 infusion of muscimol
(Mus; 0.01 lg/side; agonist at c-aminobutyric acid type A
[GABAA] receptors) 10 min before the Ext Tr expressed
less freezing behavior than the Veh-treated (saline 0.9 %)
animals during the Ext Tr. However, both groups exhibited
similar levels of freezing during the Ext Test. Additionally,
this inhibition of retrieval does not affect early persistence
of extinction when tested 7 days later or its spontaneous
recovery after 2 weeks. Furthermore, animals treated with
Veh or Mus 10 min before the Ext Tr plus anisomycin
(Ani; 80 lg/side; inhibitor of protein synthesis) or rapa-
mycin (Rapa; 5 pg/side; inhibitor of mTOR [mammalian
target of rapamycin]) immediately after the Ext Tr,
expressed higher levels of freezing behavior than the Veh
group during the Ext Test, indicating that even in the
absence of retrieval, Ani and Rapa were able to impair the
consolidation of the extinction of CFC. These findings
indicate that behavioral expression during an unreinforced
retrieval session is not necessary for the initiation, main-
tenance or spontaneous recovery of the extinction learning.
National Institute of Translational Neuroscience (INNT),
National Research Council of Brazil, and Memory Center,
Brain Institute of Rio Grande do Sul, Pontifical Catholic
University of Rio Grande do Sul (PUCRS), Porto Alegre,
Brazil. E-mail: jociane_carvalho@hotmail.com
PACAP MODULATES THE CONSOLIDATION OF
SOCIAL RECOGNITION MEMORY
S. Schmidt, C. G. Zinn, J. A. K. Behling, C. R. G. Furini,
I. Izquierdo, J. de Carvalho Myskiw
Pituitary adenylate cyclase-activating polypeptide
(PACAP) is a pleiotropic bioactive peptide that has a broad
spectrum of biological functions including neurotransmit-
ter, neurotrophic and neuroprotective. Moreover, it has
been suggested that PACAP plays an important role in the
modulation of social behavior as well as in the consolida-
tion and extinction of fear conditioning memory. In the
present study, we investigated the involvement of PACAP
in the CA1 region of the dorsal hippocampus and in the
basolateral amygdala (BLA) on the consolidation of social
recognition memory. For this, adult male Wistar rats
(3 months old) with bilateral infusion cannulae implanted
in the CA1 or in the BLA were subjected to a social dis-
crimination task. Adult animals were habituated (20 min
per day, for 4 consecutive days) to the experimental
apparatus (open field arena) and 24 h after the last habit-
uation session were exposed to a juvenile (male Wistar
rats; 21 days old) for 1 h (sample phase). Twenty-four
hours later, adults were subjected to a 5-min retention test
in the presence of the previously presented juvenile (fa-
miliar) and a second juvenile (novel). Adults that received
infusion of PACAP 6–38 (40 pg/side; antagonist of
PACAP) intra-CA1 or intra-BLA immediately after the
sample phase were not able to recognize the familiar
juvenile during the retention test, as well as the adults that
received PACAP 6–38 (40 pg/side) intra-BLA 60 min after
the sample phase. Interestingly, this impairment to recog-
nize the familiar juvenile was abolished by the co-infusion
of PACAP 6-38 plus S-Nitroso-N-acetyl-DL-penicillamine
(SNAP; 5 lg/side; nitrous oxide donor). These results
suggested that PACAP participates in the consolidation of
the social recognition memory, and that this effect seems to
occur through the action of nitric oxide.
Memory Center, Brain Institute of Rio Grande do Sul,
Pontifical Catholic University of Rio Grande do Sul
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(PUCRS), Porto Alegre, Brazil. E-mail:
jociane_carvalho@hotmail.com
ELECTROENCEPHALOGRAM OF H1KO MICE
UNDER ISOFLURANE ANAESTHESIA
T. Nakamura, T. Yoshikawa, F. Naganuma, T. Iida,
A. Karpati, T. Tamii, N. Okamura, K. Yanai
The inhaled anaesthetic isoflurane may exert loss of con-
sciousness (LOC) via the modulation of sleep/arousal
neural pathways. One of the pathways which is important
for evoking and maintaining arousal is the histaminergic
neural system. We found that the histamine H1 receptor
was involved in LOC induced by isoflurane from the
results H1KO mice behavioural experiments. However,
there was no evidence that H1 receptors in the cerebrum
were actually involved in LOC, because animal behaviours
may be a reflection of musculoskeletal abnormalities. The
aim was to elucidate whether cerebral H1 receptors are
involved in LOC induced by isoflurane induced general
anaesthesia. We measured in vivo electroencephalogram
(EEG) under various concentrations of isoflurane. H1KO
and WT mice (n = 4) underwent EEG surgery according
to the manufacturer’s protocol (Pinnacle Technology, KS,
USA). Basically the mice were anaesthetized with pento-
barbital and mounted in a stereotaxic device (Kopf, CA,
USA). A mouse EEG head-mount (Pinnacle technology)
was implanted onto the skull with four intracortical screws.
EEG screws were positioned in the frontal and parietal
cortices. 2 weeks later, EEGs were sampled for 5.5 h using
Sirenia software (Pinnacle technology). Data were ana-
lyzed by SleepSign (Kissei Comtec, Nagano, Japan) with
manual adjustments. We found that the EEG from H1KO
mice changed more rapidly to slow wave (such as theta and
delta) when compared to WT during the induction phase of
general anaesthesia. In the maintenance phase, H1KO mice
showed planarized EEG recording whereas the WT had
burst-suppression and/or spike-and-wave pattern, indicat-
ing H1KO brain activity was strongly suppressed by
isoflurane. The recovery from flat/slow wave pattern after
withdrawal of isoflurane was prolonged in H1KO group.
The EEG analysis indicated that isoflurane suppressed
neuronal activity in H1KO more strongly.
Division of Pharmacology, Faculty of Medicine, Tohoku
Medical and Pharmaceutical University, Department of
Pharmacology, Tohoku University Graduate School of
Medicine, Sendai, Japan. E-mail: tadaho@
med.tohoku.ac.jp
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HISTAMINE H3 RECEPTOR ANTAGONISTS—
FROM BENCH TO BEDSIDE AND BACK TO
BENCH
H. Stark
Histamine H3 receptor ligands have been under investiga-
tion for several decades. Initially it started with the
derivatization of the endogenous ligand histamine. With
imidazole-containing ligands as lead structure, numerous
selective and potent ligands have been developed (e.g.
thioperamide, clobenpropit, ciproxyfan). The development
of non-imidazole lead structures as antagonists/inverse
agonists gave fresh impetus to drug optimization. Several
related parent structures have been studied for pharma-
cokinetics and later also pharmacodynamics and
toxicological optimization. Pitolisant (Wakix) has been
the first important milestone making it into market for
narcolepsy as an orphan drug. The different sleep reducing,
procognitive and other effects in the central nervous system
opened the potential for the therapeutic treatment of a
number of different central disorders. Although this
potential is clear, it is unclear if the effects are robust
enough for overcoming the different therapeutic gold
standards. In that direction, others and we and others have
developed several new classes of histamine H3 receptor
antagonists with additional properties leading to multitar-
geting compounds. The polypharmacological approach
offers the chance for highly disease oriented therapeutic
drug treatment.
Heinrich-Heine-Universitaet Duesseldorf, Institut fuer
Pharmazeutische and Medizinische Chemie, Du¨sseldorf,
Germany. E-mail: stark@hhu.de
MOLECULAR PHARMACOLOGY OF THREE
ZEBRAFISH H3-LIKE RECEPTORS
D. A. McNaught-Flores, H. Puttonen, Y. C. Chen,
H. F. Vischer, P. Panula, R. Leurs
Zebrafish (Danio rerio) has emerged as an animal model
for neurodegenerative diseases due to the resemblance of
its brain structures and aminergic systems with those of
mammals. Three histamine receptors (H1R, H2R and H3R)
have been described with a sequence similarity of around
40–50 % with their human orthologs. Previously, we
reported on the cloning of two additional zebrafish H3-like
receptors and showed that all three zfH3R subtypes were
able to bind the agonist N-a-methylhistamine ([3H]-
NaMH) with similar KD values (*2 to 3 nM). Competi-
tion binding experiments with 20 human H1R, H2R, H3R,
and H4R ligands revealed that zfH3Rs show distinct
profiles. However, no information about the functional
profiles of these ligands and the signalling of the zfH3Rs
was known. In this study we investigated zfH3Rs-mediated
signalling pathways and characterize several ligand pro-
files. Real-time cAMP measurements using the BRET-
based biosensor CAMYEL showed that zfH3Rs coupled to
Gai/o proteins and agonists and antagonist were identified
for each of the three receptors. This study opens the
opportunity to discover novel compounds that can dis-
criminate between the zfH3Rs subtypes to explore their
roles in zebrafish physiology.
Amsterdam Institute for Molecules, Medicines and Systems
(AIMMS), Division of Medicinal Chemistry, Faculty of
Sciences, Vrije Universiteit Amsterdam, Amsterdam, The
Netherlands. E-mail: d.mcnaughtflores@vu.nl
ON THE EXISTENCE OF A HISTAMINE H3-
ADENOSINE A2A RECEPTOR HETEROMER
R. Marquez-Gomez, C. Gutierrez-Rodelo, M. T. Robins,
J. Escamilla-Sanchez, J. A. Olivares-Reyes, R. van Rijn,
J. A. Arias-Montan˜o
The striatum plays a major role in the modulation of motor
and cognitive processes and its deregulation leads to
pathologies such as Parkinson’s disease and addictive
behaviors. The Gai/o-coupled histamine H3 receptors
(H3Rs) are ubiquitously expressed in the striatum and
inhibit GABAergic transmission in this nucleus. The stri-
ato-pallidal neurons distinctively express Gas-coupled
adenosine A2A receptors (A2ARs) which inhibit the intra-
striatal but paradoxically facilitate the striato-pallidal
GABA release. H3Rs and A2ARs can form dimers with
dopamine D2 receptors, these interactions being potential
targets for the treatment of addiction and Parkinson’s dis-
ease, respectively. We hypothesize that H3Rs also interact
with A2ARs and that these heteromers will display a unique
pharmacology. We used a multi-pronged approach to
determine the A2AR-H3R physical interaction and func-
tionality in HEK-293 cells and in rat striatal synaptosomes.
In the cells, we first found H3R-A2AR dimerization with a
chimeric G-protein complementation assay. Using a
Glosensor cAMP assay we found that H3R activation
diminished the potency of the A2AR (pEC50 control
7.80 ± 0.30, +RAMH 6.90 ± 0.34) and increased the Emax
value from 195 ± 9 % to 314 ± 13 % of basal (n = 3,
P = 0.0007). A2AR activation completely prevented H3R-
mediated cAMP inhibition (Imax 63 ± 4 %, pIC50
8.58 ± 0.36). By using striatal synaptosomes we confirmed
the physical presence of H3R-A2AR heteromers by coim-
munoprecipitating H3Rs with A2ARs. In binding assays
H3R activation decreased the affinity of synaptosomal
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A2ARs (pKi 8.10 ± 0.04, +RAMH 7.7 ± 0.04) and in
cAMP assays prevented A2AR-induced cAMP formation.
The activation of A2ARs or H3Rs inhibited GABA uptake
by striatal synaptosomes to a similar extent (8 ± 2 % and
12 ± 3 % of control values, respectively), but co-activa-
tion resulted in an increased inhibition (22 ± 3 %, n = 3,
P = 0.0038). These data support the existence of a striatal
A2AR-H3R heterodimer capable of modulating the intra-
striatal transmission.
Department of Physiology, Biophysics and Neuroscience,
and of Biochemistry, Center for Research and Advanced
Studies of the IPN (Cinvestav), Mexico D.F., Mexico. E-
mail: ricardo.marquez3@gmail.com
A BRET-BASED KINETIC LIGAND-RECEPTOR
BINDING ASSAY FOR THE HISTAMINE H3
RECEPTOR
T. A. M. Mocking, H. F. Vischer, R. Leurs
Nowadays, ligand-receptor binding kinetics and drug-tar-
get residence time are widely accepted as important
parameters for lead compound optimization in addition to
the classically used binding affinity. Traditionally, radio-
labeled ligands are used to determine association and
dissociation rate constants of ligands either directly or
indirectly via a competition association assay. Recently, a
novel bioluminescence resonance energy transfer (BRET)
method was introduced that measures fluorescent ligand
binding to a NanoLuc-fused receptor. With this BRET
method, real-time binding on living cells can be measured,
and therefore results might better reflect in vivo conditions
as compared to the routinely used cell homogenates or
purified membrane fractions in high-throughput binding
assays. Since ligand-receptor kinetics has established its
importance in drug discovery, we aimed to setup a BRET-
based kinetics assay using a NanoLuc-fused histamine H3
receptor. In this study, we were able to measure association
and dissociation rate constants of fluorescent labeled
ligands and determine the kinetic parameters of several
unlabeled ligands via a competition association assay in
real-time on NanoLuc-fused histamine H3R, allowing us to
compare ligand-receptor residence time for a set of his-
tamine H3 receptor ligands.
Amsterdam Institute for molecules, medicines and systems,
Department of Medicinal Chemistry, Vrije Universiteit
Amsterdam, The Netherlands. E-mail: t.a.m.mocking@
vu.nl
PHARMACODYNAMICS (PD) AND
PHARMACOKINETICS (PK) OF SINGLE DOSES
OF THE NOVEL H3-RECEPTOR ANTAGONIST
IRDABIS (CEP-26401) IN COMPARISON WITH
MODAFINIL AND DONEPEZIL IN HEALTHY
VOLUNTEERS (HVs)
R. Zuiker, O. Spiegelstein, A. C. Baakman, N. Gross,
R. Yang, M. Fetell, A. Gershon, E. Hellriegel, J. van
Gerven
H3R-antagonists are in development for various disorders
with impaired cognition or hypersomnia, but clinical
results are mixed. Previous studies with the H3R-antagonist
irdabisant showed slight cognitive improvement in HVs,
but only at the lowest 20 lg dose. Higher doses caused
sleep deficits, but no cognitive effects. Detailed CNS pro-
files of low doses of irdabisant vs modafinil and donepezil
were compared. In this double-blind, placebo/positive-
controlled, partial 6-way crossover study, 40 HVs were
randomized to placebo, irdabisant (5, 25 or 125 lg),
modafinil 200 mg or donepezil 10 mg in the morning,
followed by frequent PD and PK, and polysomnography
overnight. PD was assessed with the NeuroCart, a drug-
responsive battery of neurophysiological (EEG, saccadic
(SPV) and smooth pursuit eye movements), cognitive
(verbal learning and n-back), performance (adaptive
tracking, body sway, reaction time (RT)) and subjective
tests (VAS for aspects of mood, calmness, alertness, task
enjoyment and psychotic-like). CANTAB was used for
stop-signal inhibition, rapid visual information processing,
paired associate learning (PAL) and spatial working
memory. Almost every irdabisant dose caused significant
changes in most NeuroCart tests. Subjective effects,
reflecting increased energy, alertness, mood and task
enjoyment, were largest at 25 lg. Objective improvements
of tracking, sway, SPV, RT during n-back and EEG c
power were dose-related. At the highest dose, memory
worsened slightly. Sleep reduction was also dose-related.
Modafinil had similar effects, but irdabisant’s subjective
‘energizing’ profile had a more relaxed undertone. Done-
pezil did not improve any test. Irdabisant 25 lg had the
best balance between CNS stimulation and sleep suppres-
sion. The results suggest that very low irdabisant doses
cause an optimal CNS stimulation, while higher dosages
may cause overstimulation and impaired sleep. Whether
irdabisant can have beneficial clinical effects remains to be
studied.
Centre for Human Drug Research, Leiden, The Nether-
lands. E-mail: Rzuiker@chdr.nl
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THE HISTAMINE H3-RECEPTOR PARTIAL
AGONIST OXATHRIDINE SHOWS SEDATIVE
EFFECTS BUT ALSO PAEUDO-
HALLUNCINATIONS: FIRST-IN-HUMAN
RANDOMIZED, PLACEBO CONTROLLED, SAD
STUDY IN HEALTHY VOLUNTEERS
J. Heuberger, R. Zuiker, O. Labeeuw, L. Landais, C. Denis,
T. Duvauchelle, J. van Gerven, J.-C. Schwartz
Oxathridine (BP1.5375) is a selective partial agonist of
the histamine H3 receptor (H3R). It is potentially useful
for the treatment of brain disorders such as sleep dis-
orders. Preclinical data indicate that oxathridine easily
enters the brain and increases deep sleep. This first-in-
human study was designed to assess the safety, tolera-
bility, pharmacokinetics (PK) and pharmacodynamics
(PD) of oxathridine in healthy male subjects after single
oral administrations, as compared to placebo. In this
double-blind, placebo-controlled, randomized study
(NCT01965301 in Clinicaltrials) 40 healthy male sub-
jects in 5 cohorts received single doses of oxathridine or
placebo (6:2). Oxathridine plasma concentrations and
safety were determined. NeuroCart neurocognitive tests
were performed at regular intervals. Doses ranging from
0.25 to 5 mg oxathridine were investigated, behaving
dose-linearly for Cmax and AUC, with a half-life of
2.5 h. Significant effects compared to placebo were seen
in the 2.5 and 5 mg group on adaptive tracking (-4.94
and -4.81 %), body sway (34.6 % and 43.0 %) and
saccadic peak velocity (-37.4 and -22.5 deg/s). A
significant effect compared to placebo in perception, a.o.
VAS external (0.330 log mm), was seen only in the
5 mg group. Further dose escalation was prevented by
side effects observed in the higher doses, including
(orthostatic) hypotension (1.5, 2.5 and 5 mg) and
pseudo-hallucinations (5 mg only). There were signifi-
cant sedative effects at 2.5 and 5 mg for the first hours
after dosing, but these effective doses were also
accompanied with adverse effects e.g. orthostatic
hypotension and pseudo-hallucinations. The hallucina-
tory activity elicited by H3R stimulation together with
the anti-hallucinatory activity of pitolisant in narcolepsy
suggest a role of histaminergic systems in this cognitive
parameter. Based on the NeuroCart test battery, there
was no clear separation between doses that caused
sedation and adverse effects.
Centre for Human Drug Research, Zernikedreef 8,2333 CL
Leiden, The Netherlands. E-mail: jheuberger@chdr.nl
HISTAMINE H3 RECEPTOR ANTAGONISM IS
ENHANCED BY PHARMACOLOGICAL
ASSOCIATION WITH NO DONORS IN NEW
ZEALAND WHITE RABBIT MODELS OF
GLAUCOMA
C. Lanzi., L. Lucarini, M. Durante, A. Pini, H. Stark,
E. Masini
Glaucoma is the second leading cause of blindness
worldwide, characterized by progressive optic nerve atro-
phy; it is caused by elevated intraocular pressure (IOP).
IOP reduction is the only therapeutic approach demon-
strated to preserve visual function in patients affected by
glaucoma. The first line treatment consists of topical IOP-
lowering drugs, usually as monotherapy. A significant
number of patients require more than one drug to reach a
target IOP. We previously demonstrated that the topical
treatment with H3R antagonists is effective in reducing IOP
in rabbit models of glaucoma. Prostaglandin analogues
(PGAs) are the most effective IOP lowering agents avail-
able in the market. Nitric oxide donors are successfully
associated with PGAs in the treatment of glaucoma.
Aim of this research was to evaluate the potential NO-
donor boost effect on IOP reduction obtained by
ciproxifan.
Ocular hypertension was obtained by the injection of
50 ll of hypertonic saline (5 %) into the vitreous or by
100 ll (0.1 %) of Carbomer in the anterior chamber. IOP
measurements were performed using applanation tonome-
try (Tono-Pen AVIA, Reichtert, USA) prior to saline or
Carbomer injection (baseline), immediately before drug
dosing (pre-treatment) and 1–4 h after saline injection in
the acute model and after 24 h in chronic model. All the
animals underwent Ecocolor Doppler evaluation before
and after chronic drug treatment, Pourcelot Resistance
Index (RI) was calculated.
IOP rose from 16.4 ± 3.2 mmHg at baseline to
39.4 ± 4.8 mmHgafter hypertonic saline injection and from
14.2 ± 5.3 to 36.8 ± 5.6 four days after Carbomer injection.
Ciproxifan and molsidomine (0.1, 0.3, 0.5, 1 %) dose-de-
pendently reduced IOP at 60’ after saline injection (0.5 % p
value\0.05, 1 % p value\0.01). The ciproxifan/mol-
sidomine combination that produced the higher IOP
reductionwas 0.5/0.5 %. IOP andmean resistance index (RI)
of retinic artery were significantly reduced by this combi-
nation in the chronic model setting (p value\0.01 at day 10,
12 and 13 for IOP; p value\0.05 for RI).
Histaminergic H3R antagonists confirmed to be an
interesting new therapeutic option for the treatment of
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glaucoma and the association with a NO-donor compound
showed a synergic effect boosting the IOP lowering effi-
cacy and ameliorating the vascular performance of the
retinic artery.
Departments of NEUROFARBA, Section of Pharmacology,
and Experimental and Clinical Medicine, University of
Florence, Italy. E-mail: cecilia.lanzi@unifi.it
DIFFERENTIAL HOMOLOGOUS
DESENSITIZATION OF THE HUMAN HISTAMINE
H3 RECEPTORS OF 445 AND 365 AMINO ACIDS
A. M. Garcı´a-Ga´lvez, C. Flores-Clemente, R. Gonza´lez-
Pantoja, J. Escamilla-Sa´nchez, J. A. Arias-Montan˜o
Histamine H3 receptors (H3Rs) are found in neuronal cells
as auto- and hetero-receptors. Alternative splicing of the
human H3R (hH3R) could generate at least 20 isoforms,
and in addition to the hH3R445 an isoform of 365 amino
acids (hH3R365) is widely expressed. Homologous desen-
sitization, a major mechanism to regulate the function of G
protein-coupled receptors (GPCRs), is triggered by the
phosphorylation of activated receptors by GPCR kinases
(GRKs) and we have shown that the hH3R445 stably
expressed in CHO-K1 cells experiences homologous
desensitization. The hH3R365 lacks 80 residues in the third
intracellular loop, an important region for GPCR coupling
to G proteins, as well as for the phosphorylation by GRKs
in the homologous desensitization mechanism. In this
work, we aimed to study whether the hH3R365 experiences
homologous desensitization and the possible differences
with the hH3R445 isoform. Both hH3R isoforms were stably
expressed in CHO-K1 cells, receptor levels were deter-
mined by [3H]-N-a-methyl-histamine binding assays and
functional desensitization was evaluated in cells pre-incu-
bated with the H3R agonist R-a-methyl-histamine
(RAMH). The lack of 80 residues in the hH3R365 had no
effect on the expression by CHO-K1 cells, the affinity for
selective ligands or the presence on the cell surface. Pre-
incubation for 30 min with RAMH (1 lM) reduced by
58 ± 8 % hH3R365 Gai/o-mediated signaling and resulted
in the loss of receptors from the cell surface, as well as in
reduced affinity for immepip. Maximal functional desen-
sitization differed in both the extent (96 ± 15 and
58 ± 8 % for hH3R445 and hH3R365, respectively) and the
length of exposure required (60 and 30 min). Furthermore,
at 60 and 120 min of RAMH pre-incubation, the hH3R365
showed partial re-sensitization, whereas the hH3R445
remained desensitized. These results indicate that the
hH3R365 experiences homologous desensitization, but the
process differs from the hH3R445 in time-course, magnitude
and re-sensitization.
Departamento de Neurociencias, Centro de Investigacio´n y
de Estudios Avanzados (Cinvestav) del IPN, Me´xico, D.F.,
Mexico. E-mail: anikcson_06@hotmail.com
EVALUATION OF HISTIDINE DECARBOXYLASE
ACTIVITY AND HUMAN HISTAMINE H3
RECEPTOR (H3R) AND HISTIDINE
DECARBOXYLASE (HDC) mRNA LEVELS
C. Acosta-Andrade, J. L. Urdiales, I. Fajardo,
F. Sa´nchez-Jime´nez
Histamine plays pleiotropic roles in human pathophysiol-
ogy that are dependent of both the capability to be
synthesized in a given environment and the cell-specific
combination of histamine receptors expressed in the dif-
ferent human cell types. At present, characterization of the
molecular bases of the tissue-specific roles of the histamine
metabolism-related elements (HMRE) requires further
research efforts in order to fully explain the multiple his-
tamine roles in human pathophysiology and to develop new
intervention possibilities derived from this knowledge. To
this purpose, we have developed some methods for years to
approach expression estimation of histamine HMRE in
different human cell types and tissues. They are a radio-
labelled method for mammalian histidine decarboxylase
(HDC) activity measurement, and qRT/PCR methods for
quantification and transcript analyses of human HDC and
human histamine H3 receptor (H3R). As a result, we have
provided an interesting and reproducible tool for the
analysis of the HMRE to gain insight into histamine roles
in human tissues and cell types.
This work was supported by SAF2011-26518
(MINECO, Spain) and P10-CVI-6585 and Bio-267 (Junta
de Andalucia, Spain). CIBERER is an initiative of Instituto
de Salud Carlos III (Spain).
Department of Molecular Biology and Biochemistry, Fac-
ulty of Sciences, Andalucı´a Tech, University of Ma´laga,
Ma´laga, Spain. E-mail: sanks737@hotmail.com
CHARACTERIZATION OF N-SUBSTITUTED-N-[4-
(4-(7-PHENOXYHEPTYL) PIPERAZIN-1-
YL)BUTYL]GUANIDINES AS HISTAMINE H3
RECEPTOR ANTAGONISTS
A. Olejarz, M. Staszewski, T. Karcz, K. Walczynski,
K. Kiec-Kononowicz
Histamine H3 receptors (H3R) are involved in the central and
peripheral regulation of histamine levels. By postsynaptical
modulation they regulate the levels of other
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neurotransmitters, such as ACh, 5-HT, NA and NPY.
Therefore, the blockade of H3R might provide useful phar-
macological target in the treatment of CNS-based diseases,
which has been confirmed by intensive pharmacological
studies. In present study, we evaluated the group of N-sub-
stituted-N-[4-(4-(7-phenoxyheptyl)piperazin-1-
yl)butyl]guanidine derivatives as a potent H3R antagonists.
Considered structures were selected basing on preliminary
screening results obtained in electrically evoked contraction
of the guinea-pig jejunum assay. The antagonistic properties
at H3R were confirmed in cAMP accumulation assay.
Moreover, radioligand binding assays towards H3R and off-
target histamine H4 receptor (H4R) allowed for determina-
tion of respective Ki values and consequently enabled the
characterization of compounds selectivity. For two selected
compounds the following safety parameters were evaluated
in vitro: hERG channel inhibition (automated patch-clamp
technique), mutagenicity (Ames test) and hepatotoxicity
(proliferation assay at human HepG2 cells).Evaluated
guanidines showed affinity towards histamine H3R in sub-
micromolar concentration range and represented up to
20-fold selectivity over H4R. Moreover, the considered
structures showed good safety index in performed experi-
ments and therefore could be considered as a promising
structural scaffold for further development of H3 histamine
receptor ligands.
We acknowledge the financial support of the Polish
National Science Center grants, No.: UMO-2011/01/N/
NZ4/01126 and UMO-2011/02/A/NZ4/00031.
Department of Technology and Biotechnology of Drugs,
Jagiellonian University Medical College, Krako´w, Poland.
E-mail: agnieszka.olejarz@uj.edu.pl
NEW N-(4-PHENOXYALKYLPIPERAZIN-1-
YL)ALKYLGUANIDINES, POTENT AND BRAIN-
PENETRATING NON-IMIDAZOLE HISTAMINE H3-
ANTAGONISTS
A. Stasiak, M. Staszewski, K. Walczyn´ski, W. A. Fogel
The guanidine derivatives, both imidazole and non-imida-
zole class, are potent and selective histamine H3 receptor
antagonists. Previously, we reported the synthesis and
biological evaluation of N-substituted-N-[x-(x-phenoxy-
heptylpiperazin-1-yl)butyl]guanidines. Detailed structure–
activity studies revealed that a halogen at position 4 in the
benzene ring leads to compounds with lower activity
(pA2 = 7.89–7.80) than their unsubstituted analogue
(pA2 = 8.21). Here we report on further in vivo pharma-
cological studies that were done for N-benzyl-N-[4-(7-
phenoxyheptylpiperazin-1-yl)butyl]guanidine and N-4-
chlorobenzyl-N-[4-(7-phenoxyheptylpiperazin-1-yl)butyl]
guanidine. Lewis rats, males, 8-wk. old, were placed and
kept individually in metabolic cages, their fluid and feed
consumptions were recorded daily in the morning. After
3 days with no treatment (control period) they were ran-
domly given one of the two compounds or Ciproxifan
hydrogen maleate as a reference H3R antagonist (3 mg/kg
s.c., each). The treatment was continued for 5 days. The
following morning, after consumptions recording, the rats
were decapitated, their brains collected frozen and kept at
-80 C until binding studies were performed. Histamine
H3 receptors were assayed with [
3H] R-a-methyl histamine
ligand. The results obtained indicate that the examined
compounds penetrate the blood–brain barrier, with their
H3R antagonistic activity being lower (N-benzyl-N-[4-(7-
phenoxyheptylpiperazin-1-yl)butyl]guanidine) or similar
(N-4-chlorobenzyl–N-[4-(7-phenoxyheptylpiperazin-1-yl)
butyl]guanidine) to that of Ciproxifan. This work was
supported by MUL (i.e. Med Uni Lodz) 503/5-087-02/503-
01 and 500/3-016-01/503-31-001.
Departments of Hormone Biochemistry, and of Synthesis
and Technology of Drugs, Medical University of Lodz. E-
mail: weislawa.agnieszka.fogel@umed.lodz.pl
DIFFERENCES IN b-ARRESTIN2 RECRUITMENT
BY HUMAN H3R ISOFORMS AS DETERMINED BY
ENZYME FRAGMENT COMPLEMENTATION
S. N. Rahman, F. Imhaouran, R. Leurs, H. F. Vischer
The human H3 receptor (hH3R) receptor gene encodes for
20 hH3R isoforms as a consequence of alternative splicing
and they are differentially expressed within the CNS. The
hH3R-445 -415, -365 and -329 isoforms conserve the
prototypical 7TM domains, but have different IL3 loop
truncations. Therefore, they are known to have different
pharmacological and signaling profiles. Although hH3R
isoforms are known to signal via Gai, it is unknown if they
can mediate G protein-independent signaling and regula-
tion (i.e. desensitization and internalization via b-arrestin1/
2). For the closely related human H4 receptor (hH4R)
(*60 % amino acid sequence similarity) b-arrestin2
recruitment was recently reported. In this study, b-arrestin2
recruitment at hH3R isoforms is compared using Enzyme
Fragment Complementation technology. Our results indi-
cate differences in pharmacological profiles (i.e. potency,
efficacy and mode of action) of hH3R ligands between
hH3R isoforms. For instance, H3 ligand immepip (full
agonist in G protein signaling) was found to be a partial
agonist for hH3R-445 (a = 0.4), hH3R-415 (a = 0.5),
hH3R-365 (a = 0.8) and hH3R-329 (a = 0.9). Moreover,
imetit (full agonist in G protein signaling) was found to be
a selective agonist for hH3R-365 and hH3R-329, but an
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antagonist for hH3R-445 and hH3R-415. Stimulation with
agonists N-alpha-methylhistamine (NaMH) and R-alpha-
methylhistamine (RaMH) resulted in higher potencies for
hH3R-365 and hH3R-329, as compared to hH3R-445 and
hH3R-415. This study reveals differences in pharmaco-
logical profiles of H3 ligands on b-arrestin2 recruitment
between hH3R isoforms, presumably caused by differences
in the IL3 loop.
Amsterdam Institute for Molecules, Medicines and Systems
(AIMMS), Division of Medicinal Chemistry, Faculty of
Sciences, Vrije Universiteit, Amsterdam, The Netherlands.
E-mail: s.n.rahman@vu.nl
HISTAMINE H3-RECEPTORS MAY BE INVOLVED
IN THE PRODUCTION OF CYTOKINES AND
CHEMOKINES DURING MUSIC THERAPY AND
OTHER NON-DRUG INFLUENCES
R. Khanferyan, C. Gigante Pe´rez, V. Randriantsalama, F.
Diel
The discovery of histamine H3-receptors as presynaptic
autoreceptors on histamine-containing neurons and on
peripheral tissues support an idea that histamine effects
during non-immunological, non-drug influences respond
partly via this type of receptor. Furthermore, diverse
expression of H3-receptors throughout the brain can mod-
ulate the release many neurotransmitters. Our previous
investigations have demonstrated that antagonists of H3-
receptors modulate pro- and anti-inflammatory cytokine
synthesis in patients with acute sensorineural hearing loss
(ONT). It is well known that non-drug factors can produce
equivalent outcomes of the clinical symptoms producing a
much shorter onset time and less overall risk and cost, than
pharmacological therapies. One of such non-medication
factors is music therapy (MT). Effects of MT on behavioral
and psychological symptoms have been demonstrated in
various clinical situations. MT has been used before and
after surgical interventions, in psychotherapy of behavior
disturbances such as aggression, disruption, shadowing,
depression, repetitive behaviors and in complex manage-
ment of dementia. It has been shown that music enhances a
variety of cognitive functions e.g. attention, learning,
communication and memory. Recent studies have demon-
strated that music can decrease cortisol and
adrenocorticotropin releasing hormone (ACTH). In our
previous studies we have demonstrated that different types
of music may influence salivary histamine secretion in
allergic and non-allergic young volunteers. The aim of this
study was to demonstrate that MT and ONT influence H3-
receptor activity and regulation. Using peripheral blood
mononuclear cells (PBMC) and dendritic cells derived
from PBMC of 12 healthy volunteers cultivated with H3/4
dual antagonist Ciproxifan (10-5 M) as well as H3/4
agonist N-Methyl-1H-imidazole-4-ethanamine (Na-
methylhistamine) (10-5 M) using multiplex technology,
we found that histamine modulated the production of
multiple immunoregulatory cytokines, chemokines and
growth factors via H3-receptors.
Institute of Nutrition, Moscow, Russian Federation. E-
mail: khanferyan@ion.ru
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THE HISTAMINE H4 RECEPTOR MEDIATES
CHEMOTAXIS OF HUMAN LUNG MAST CELLS
L. Kay, P. Peachell
Previous studies by others have shown that histamine
induces chemotaxis of mouse mast cells by engaging the
H4 receptor (H4R). The aim of the present study was to
determine whether the H4R mediates chemotaxis of human
lung mast cells (HLMC). HLMC were generated by
physical and enzymatic disruption of lung tissue obtained
from surgical resections. Isolated HLMC were further
purified by Percoll density gradient centrifugation and
chemotaxis assays performed using ChemoTx system
(8 lm pore size). On average, 20,000 HLMC were loaded
per condition, with or without the selective H4R agonist
JNJ28610244 (10 lM). Stem Cell Factor (SCF, 10 ng/ml),
a known HLMC chemoattractant, was used as a positive
control. The plate was incubated (4 h, 37 C) in a CO2
incubator, and the number of mast cells migrating to the
bottom chamber evaluated using the mast cell specific
stain, alcian blue. The effects of the selective H4R antag-
onist JNJ7777120 (10 lM) against JNJ28610244 were also
investigated. In additional functional studies, HLMC were
incubated (25 min) with JNJ28610244 (10 lM) and his-
tamine released into the supernatants assayed using an
automated fluorometric technique. ANOVA was performed
(GraphPad V6) to determine whether the effects were
significant. JNJ28610244 was an effective inducer
(P\ 0.001) of HLMC chemotaxis, causing a 3-fold
increase in migration over control (n = 9). SCF was at
least as effective (P\ 0.001) at inducing mast cell
migration (n = 17). In further studies (n = 4), the H4R
antagonist JNJ7777120, reversed chemotaxis induced by
JNJ28610244 by *64 % (P\ 0.05). In functional studies
(n = 11) JNJ28610244 did not induce histamine release in
HLMC. These data indicate that activation of the H4R
mediates chemotaxis of HLMC.
Academic Unit of Respiratory Medicine, The University of
Sheffield, Sheffield, UK. E-mail; l.j.smart@sheffield.ac.uk
HUMAN H4R SIGNALING AND DESENSITIZATION
E. W. E. Verweij, R. Leurs, H. F. Vischer
The human histamine 4 receptor (hH4R) is mainly
expressed on cells of hematopoietic origin and involved in
allergic and inflammatory diseases. Agonist-induced acti-
vation of G protein-coupled receptors (GPCRs) leads to
signaling via G proteins and subsequent receptor desensi-
tization by G protein-coupled receptor kinases (GRKs) and
b-arrestin recruitment. In this study, signaling and desen-
sitization of the hH4R is investigated by making use of
fusion constructs and bioluminescence resonance energy
transfer (BRET)-based assays in response to chemically
distinctive hH4R agonists. This study shows that the hH4R
signals via Gai1, Gai2 and Gai3 proteins without preference
towards a specific isoform. Signaling regulated by other G
protein subtypes, respectively Gas, Ga13 and Gaq, could
not be observed. Furthermore, activation of the hH4R leads
to rapid translocation of intracellular GRK2 and 3 towards
the cell membrane and b-arrestin1 and 2 recruitment,
demonstrating the occurrence of receptor desensitization.
Understanding the molecular aspects of both the signaling
and regulatory mechanisms of the hH4R are important for
drug development.
Amsterdam Institute for Molecules Medicines and Systems,
Division of Medicinal Chemistry, Faculty of Science, Vrije
Universiteit Amsterdam, The Netherlands. E-mail:
n.verweij@vu.nl
THE PHARMAOCLOGY AND CLINICAL
DEVELOPMENT OF TOREFORANT,
A HISTAMINE H4 RECEPTOR ANTAGONIST
R. L. Thurmond
Toreforant (JNJ 38518168) is a potent antagonist of the
H4R with an inhibition constant (Ki) of 8.4 nM at the
human H4R and greater than 25-fold selectivity over other
histamine receptors. The compound is less potent at the
mouse H4R with a Ki of approximately 300 nM. Tore-
forant is efficacious in mouse models of arthritis, asthma
and dermatitis. In a mouse CIA model treatment of animals
with toreforant at 100 mg/kg BID lead to a reduced man-
ifestation of disease as judged by the severity score and
blinded histological analysis of joint pathology. Repeat-
dose chronic toxicity studies in rats (6 months of daily
dosing) and monkeys (9 months of daily dosing) indicated
an excellent safety profile supporting the clinical testing of
the compound. An oral formulation of toreforant was
studied in a phase 1 human volunteer study to assess safety,
pharmacokinetics and pharmacodynamics. The compound
was well-tolerated at all doses tested and exhibited good
pharmacokinetics upon oral dosing. In addition, dose
dependent inhibition of histamine-induced eosinophil
shape change was detected suggesting that the H4R was
inhibited in vivo. Phase 2 clinical studies have been con-
ducted in patients with rheumatoid arthritis, asthma or
psoriasis.
Janssen Research & Development, San Diego, CA, USA. E-
mail: rthumon@its.jnj.com
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CHARACTERIZATION OF BEHAVIORAL
PHENOTYPES IN HISTAMINE H4-RECEPTOR
KNOCKOUT MICE
M. D. Sanna, N. Galeotti, L. Lucarini, M. Durante,
C. Ghelardini, R. Thurmond, E. Masini
Histamine mediates a wide range of physiological func-
tions through binding to four known histamine receptors.
The recently cloned histamine receptor H4 is functionally
expressed in the central nervous system, although this
remains controversial. The aim of this study was to
characterize the behavioral phenotypes of H4R knockout
mice to understand the role of H4R in mediating his-
tamine effects. We characterized the behavior of H4R-
KO and wild-type mice by subjecting them to a range of
behavioral tests (n = 10 per genotype, 3 months of age).
H4R-KO mice showed a slightly increased spontaneous
mobility and exploratory activity in the hole board test,
without any deficit in the rotarod test. The H4R-KO mice
had no cognitive impairment in the novel object recog-
nition and passive avoidance tasks. However, KO
mice differed from their WT in the mood-related behav-
ioral tests. H4R-KO mice exhibited an anxiety-
like phenotype in the light/dark box test (P\ 0.01) and, a
trend toward a depressive-like phenotype in the tail sus-
pension test (P\ 0.05). We also examined whether food
intake changes under a condition of food deprivation,
were altered in H4R-KO mice. H4R-KO mice manifested
orexigenic phenotype that is characterized by increase in
food intake in non-food deprived mice (P\ 0.001). H4R-
KO mice exhibited normal pain sensitivity after thermal
and mechanical stimulus. We have previously demon-
strated that neuronal H4R is involved in neuropathic pain
transmission. To validate the involvement of H4R
in pain sensation, Von-Frey and Plantar tests were per-
formed before and after spared nerve injury (SNI) in H4R-
KO mice. We found that H4R-KO mice that underwent
SNI surgery showed decreased ipsilateral paw withdrawal
threshold (P\ 0.01), indicating the important role of H4R
in the histamine-mediated modulation of pain transmis-
sion. The behavioral characterization of H4R-KO mice
has demonstrated important roles of neuronal H4R in the
regulation of behaviors like anxiety, regulation of food
intake and pain perception, suggesting that neuronal his-
tamine is a mediator of these neuronal functions
through H4R in mice.
Department of Neurosciences, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-
ence, Florence, Italy. E-mail: maria.sanna@unifi.it
THE SELECTIVE HISTAMINE H4 RECEPTOR
ANTAGONIST JNJ 777120 IS PROTECTIVE IN
A RAT MODEL OF TRANSIENT CEREBRAL
ISCHEMIA
I. Dettori, A. Melani, L. Lucarini, E. Masini, F. Pedata
Histamine is an important neurotransmitter or neuromodu-
lator in the Central Nervous System (CNS). Recently,
numerous studies have suggested that histamine and its
receptors play important roles in cerebral ischemia. In the
experimental model of focal cerebral ischemia induced by
occlusion of the middle cerebral artery (MCAo) in rats, the
levels of histamine evaluated by microdialysis increase in the
ischemic areas. The human histamine H4 receptor is the most
recently discovered member of the G protein-coupled
receptor subfamily of histamine receptors. It is predominantly
expressed in several cell types of immune system and in
numerous areas of the CNS. Characterization of the H4
receptor as the immune system histamine receptor with a pro-
inflammatory role directed growing attention towards its
therapeutic exploitation in chronic inflammatory disorders.
The aim of our study was to assess the putative neuropro-
tective effects of the potent and selective H4 receptor
antagonist, JNJ7777120, chronically administered (1 mg/kg,
i.p., twice/day for 7 days) on damage parameters in a model
of focal ischemia induced in the rat by the transient (1 h)
occlusion of the medial cerebral artery (tMCAo) by the
monofilament technique. JNJ7777120, significantly pro-
tected from the neurological deficit 1 day after tMCAo (score
at 1 day: 5.50 ± 0.43, n = 6 versus 9.33 ± 0.88, n = 6 in
vehicle group; p\ 0.001). Chronic treatment with
JNJ7777120 significantly reduced body weight loss at 5 and
7 days after tMCAo compared to vehicle-treated rats
(p\ 0.001). Seven days after the ischemic insult,
JNJ7777120, significantly reduced the volume of the
ischemic cortical damage (20.5 ± 2.5 mm3, n = 6 versus
28.3 ± 1.7 mm3, n = 6 in vehicle group; p\ 0.03) and the
volume of the ischemic striatal damage (4.7 ± 0.7 mm3,
n = 6 versus 10.75 ± 1.9 mm3, n = 6 in vehicle group;
p\ 0.015). JNJ7777120 did not significantly reduce plasma
levels of the proinflammatory cytokines, IL-1b and TNF-a.
Results indicate that the selective antagonist of histamine H4
receptor, JNJ7777120, systemically and chronically admin-
istered after ischemia, reduces the ischemic brain damage and
improves the neurological deficit. This study was supported
by grants from the Ente Cassa di Risparmio of Florence, Italy.
Department of Neuroscience, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-
ence, Florence, Italy. E-mail: ilaria.dettori@unifi.it
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EFFECTS OF SELECTIVE HISTAMINE H4
RECEPTOR LIGANDS ON CROTON OIL-INDUCED
SKIN INFLAMMATION AND PRUITUS IN MICE
M. Adami, C. Micheloni, D. Grandi, H. Stark
In the present study, some structurally related ligands
characterized for their different H4R efficacies (partial
agonism, neutral antagonism, partial inverse agonism, and
inverse agonism) were tested in vivo against croton oil
(CO)-induced ear edema and pruritus in mice. Ear weight
and histological tissue damage were investigated 2 h after
CO application and pruritus was evaluated 1 h after. The
H4R ligands (10–100 mg/kg) were administered subcuta-
neously (sc) immediately before the topical application of
the irritant agent. Among the compounds tested, the neutral
antagonist ST-994 and the hH4R inverse agonist ST-1012
(Emax = -110.7 %) induced at 30 mg/kg a 46.36 and
35.16 % inhibition of ear edema, respectively, while the
partial agonist ST-1006 (Emax = 28.4 %) and the partial
inverse agonist ST-1124 (Emax = -73.6 %) were ineffec-
tive. CO induced a significant increase in dermis thickness,
edema and leukocyte infiltration into perivascular spaces
and in the interstitium. At the anti-inflammatory dose of
30 mg/kg, ST-994, but not ST-1012, significantly reduced
the total severity score in all the areas examined and the
number of eosinophils in inflamed tissue (60.57 % inhibi-
tion), while the total number of mast cells was not
significantly modified. Ear instillation of CO induced
scratching in all treated mice. CO-induced pruritus was not
changed by ST-1012 at 30 mg/kg, whereas it was signifi-
cantly reduced by ST-1006, ST-1124 or ST-994 (64.10,
53.62 and 65.91 % inhibition, respectively). Taken toge-
ther, these data indicate that CO-induced ear inflammation
and pruritus seem to be variably affected by the H4R
ligands tested. The potential advantage of the dual effect of
the hH4R neutral antagonist ST-994 in this chemically-
induced skin inflammation model needs additional studies.
Department of Neuroscience, Unity of Pharmacology,
University of Parma, Italy. E-mail:
maristella.adami@unior.it
ANALYSIS OF THE FUNCTION OF THE
HISTAMINE H4-RECEPTORS ON MURINE TYPE 2
INNATE LYMPHOID CELLS (ILC2) ACTIVITY
C. L. Rehfeld, B. Schirmer, D. Neumann
In an asthmatic inflammatory response, the regulation of
the recruitment, activation, growth, differentiation and
survival of eosinophils by interleukin (IL)-5 plays a key
role. Consequently, IL-5 antibodies can be considered
useful for the treatment of asthma patients to prevent the
recruitment of eosinophils causing local inflammation in
the lung. Ovalbumin (OVA)-induced experimental allergic
asthma in mice provides a good model to study the asth-
matic inflammatory response. Recently, we demonstrated
that the production of IL-5 in the effector phase is depen-
dent on the expression of the histamine H4-receptor (H4R).
However, the cell type responsible for the H4R-regulated
local production of IL-5 remained elusive. The recently
identified type 2 innate lymphoid cells (ILC2) are a major
source for IL-5. Therefore, we asked whether ILC2 pro-
duce IL-5 in a histamine/H4R-dependent manner. In
inflammation the activity of ILC2 is regulated by cytokines
(IL-25, IL-33, TSLP) originating from epithelial cells.
Thus, the H4R-mediated regulation of ILC2 may be direct
or indirect. In order to analyze a possible regulation of
ILC2 by histamine, we established an in vitro assay. ILC2
and epithelial cells were isolated from mouse intestine and
lung. In the obtained cells the expression of H4R was
analyzed by specific RT-qPCR. Functionally, ILC2 and
epithelial cells were activated in vitro and treated with
histamine or H4R-selective agonists in the absence or
presence of H4R-selective antagonists, and IL-5 secretion
(in the supernatants) were quantified by ELISA. Our data
indicate that histamine via the H4R directly modulates the
induced production of IL-5. Our preliminary data show that
histamine decreased IL-5 secretion (n = 2, p\ 0.01 Stu-
dent’s T-test, two-tailed). Whether an indirect modulation
also takes place is matter of ongoing investigations. This
study provides evidence that the in vivo effect of the H4R
on IL-5 production in the in vivo asthma model may be
based on H4R function on ILC2 activation. This, however,
has to be proved in our future studies.
Hannover Medical School–Institute of Pharmacology,
Hannover, Germany. E-mail: rehfeld.christopher@mh-
hannover.de
JNJ39758979 PREVENTS THE PROGRESSION OF
DIABETIC NEPHROPATHY
A. Pini, E. Veglia, C. Grange, M. Argenziano, R. Cavalli,
R. Fantozzi, R. L. Thurmond, P. L. Chazot, A. C. Rosa
Due to the paucity of effective therapy, diabetic
nephropathy is one of the major clinical and public health
challenges, for which the pursuit of a new therapeutic
strategy is a priority. Our previous data have identified the
H4R as a promising pharmacological target within this
context. The aim of this study was to evaluate the efficacy
of the selective H4R antagonist JNJ39758979 (JNJ) on
preservation of renal function and morphology in a murine
model of diabetic nephropathy. Hyperglycaemia was
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induced in DBA/2J 7–8 week-old male mice by using the
multiple low-dose streptozotocyn (STZ)-injection protocol.
JNJ was administered daily by oral gavage at doses of 25,
50, 100 mg/kg. Urine was processed fortnightly for stan-
dard urinalysis. At week 15 mice were sacrificed and blood
and kidneys were collected for biochemical and morpho-
logical analysis. The glycaemic level rose by greater than
200 mg/dl within 14 days and remained severely elevated
throughout the observation period. Despite the increase in
food consumption, the weight gain of STZ-mice was sig-
nificantly reduced over time (P\ 0.05 vs control). JNJ did
not significantly affect either glycaemic status or body
weight, but showed a trend in reducing STZ-induced water
intake. Urine collection suggested a dose-dependent inhi-
bitory effect of JNJ on the urine volume excreted in a 24 h
sample period, with animals treated for 15 weeks at
100 mg/kg excreting 10 ml/24 h urine vs 28 ml/24 h
(P\ 0.05) by animals treated with STZ alone. In addition,
a significant increase in proteinuria and albuminuria was
observed in diabetic mice over time. JNJ at 50 and 100 mg/
kg significantly reduced proteinuria (by 58 and 43 %,
respectively), with the highest dose completely effective
also on albuminuria (P\ 0.05). These beneficial effects of
JNJ were confirmed by morphological analysis. JNJ was
effective in preserving the renal function and morpholog-
ical integrity. Thereby, our data provide the first evidence
supporting the use of JNJ to counteract diabetic
nephropathy.
Dept. of Clinical and Experimental Medicine, University of
Florence, Florence, Italy. E-mail: arinnacarolina.rosa@
unito.it
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Molecular and genetic aspects and adverse reactions of histamine, its receptors
and antihistamines
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RESIDENCE TIME OF ANTIHISTAMINES AND ITS
EFFECT ON SIGNALING OF THE HISTAMINE H1
RECEPTOR
R. Bosma, S. Kuhne, I. Josimovic, R. Moritani, C. de Graaf,
I. J. P. de Esch, H. F. Vischer, R. Leurs
In the body, concentrations of (endogenous) ligands are
dynamic due to processes such as absorption, distribution,
metabolism and excretion (ADME). This dynamic nature
makes it hard to predict the effect of an antihistamine based
on just its affinity constant, which only accurately predicts
receptor occupancy under stable conditions (equilibrium).
The dissociation rate predicts how long a ligand resides on
the receptor (residence time), which is considered to be an
important metric for drug effectiveness. Based on the
specific dynamics of both histamine and antihistamine
concentrations, the residence time of antihistamines could
imply a stronger histamine inhibition then expected based
on the affinity and drug concentration of both ligands. For
antihistamines, residence times are often measured using
radioligand binding experiments on cell membranes
against an arbitrary radioligand. In this study it was
explored whether the dissociation rates of antihistamines
could also be directly derived from functional experiments
on whole cells in competition with histamine. Different
functional experiments were evaluated for their response
over time upon stimulation with histamine and antihis-
tamines and used to determine ligand residence times. It
was shown that these methods allowed the discrimination
of ligands based on their residence times.
The presenter of this abstract was the runner-up of the
Young Investigator Award (2016).
Amsterdam Institute for Molecules Medicines and Systems,
Division of Medicinal Chemistry, Faculty of Science, Vrije
Universiteit, Amsterdam, The Netherlands. E-mail:
reggiebosma@hotmail.com
EFFECT OF NARROW-BAND UVB ON UP-
REGULATION OF HISTAMINE H1 RECEPTOR
GENE EXPRESSION
K. Okamoto, H. Mizuguchi, T. Fujii, T. Yamada,
Y. Kitamura, N. Takeda, H. Fukui
Ultraviolet B (UVB) irradiation shows many biological
effects based on its specific spectrum. Clinically, narrow-
band (NB)-UVB at 308–313 nm has a therapeutic effect in
atopic dermatitis. As allergic rhinitis (AR) shares several
common pathogenic features with atopic dermatitis that are
successfully treated with NB-UVB phototherapy, applica-
tion of NB-UVB phototherapy for AR is expected.
Histamine is a major chemical mediator of the allergic
reaction; its action is mainly mediated through the activa-
tion of histamine H1 receptor (H1R). We demonstrated that
H1R gene expression is correlated with the nasal symptom
severity in patients with pollinosis and compounds that
suppress the H1R upregulation alleviates nasal symptoms
in toluene-2,4-diisocyanate (TDI)-sensitized rats (N = 4,
6 week old, male, Brown Norway rat.). We also showed
that PKCd is involved in H1R transcription and its acti-
vation by phorbol 12-myristate 13-acetate (PMA) increased
the expression of H1R at both mRNA and protein levels in
HeLa cells. Here, we investigated the effects of irradiation
with 310 nm NB-UVB on PMA-induced upregulation of
H1R mRNA in HeLa cells and on the TDI-induced nasal
symptoms and H1R mRNA upregulation in TDI-sensitized
rats [control = 1; TDI = 1.98, P\ 0.01 vs control;
TDI + 310 nm (200 mJ/cm2) = 1.48; TDI + 310 nm
(600 mJ/cm2) = 1.27, P\ 0.01 vs TDI]. Irradiation with
305 nm UVB and 310 nm NB-UVB, but not 315 nm UVB
at a dose of 200 and 300 mJ/cm2 significantly suppressed
PMA-induced H1R mRNA up-regulation. (at a dose of
200 mJ/cm2: control = 1; PMA = 3.18; PMA +
305 nm = 0.24, PMA + 310 nm = 1.08, P\ 0.0001 vs
PMA; PMA + 315 nm = 2.56. At a dose of 300 mJ/cm2:
control = 1; PMA = 2.07; PMA + 305 nm = 0.36,
PMA + 310 nm = 1.72, P\ 0.0001 vs PMA;
PMA + 315 nm = 1.91, P\ 0.05 vs PMA). At a dose of
200 mJ/cm2, irradiation with 310 nm NB-UVB did not
induce apoptosis, although 305 nm UVB did. Irradiation
with 310 nm NB-UVB at the dose of 200 mJ/cm2 sup-
pressed PMA-induced ERK phosphorylation, while PKCd
phosphorylation was not affected. Pretreatment with
310 nm NB-UVB significantly suppressed TDI-induced
nasal symptoms and H1R gene upregulation in TDI-sensi-
tized rats. [control = 1; TDI = 1.98, P\ 0.01 vs control;
TDI + 310 nm (200 mJ/cm2) = 1.48; TDI + 310 nm
(600 mJ/cm2) = 1.27, P\ 0.01 vs TDI]. Data suggest that
low dose irradiation with 310 nm NB-UVB suppressed
upregulation of H1R gene expression without inducing
apoptosis, resulting in the reduction in the nasal symptoms
in TDI-sensitized rats, and could be useful for AR
phototherapy.
Departments of Molecular Pharmacology, Otolaryngology,
and Molecular Studies for Incurable Diseases, Institute of
Medical Biosciences, Tokushima University Graduate
School, Tokushima, Japan. E-mail: okamotokentaro4124@
yahoo.co.jp
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HISTAMINE AND ITS RECEPTORS AS A MODULE
OF THE BIOGENIC AMINE DISEASOME
R. Rodrı´guez-Lo´pez, M. Morales, A. Reyes-Palomares,
F. Sa´nchez-Jime´nez
Biogenic amines play important roles in the most important
physiological processes, from cell proliferation and differ-
entiation to nutrition, immune response, neurobiology and
reproduction. These effects are spread through a wide vari-
ety of cell-specific receptors, and cell-specific signaling and
metabolic pathways. However, the biochemical events
underlying these effects conforms very complex networks of
interactions that are far of being completely understood in
most cases. In addition, two or more biogenic amines can
coexist in the same physiological scenarios maintaining
cross-talk events with influence in their respective physio-
logical functions. In this sense, histamine seems to be the
most pleotropic biogenic amine maintaining biochemical
and functional interactions with both growth-related
polyamines and neurotransmitters in different cell models
and tissues. As diseases are the consequence of a bio-
chemical imbalance in one or more tissues, the physiological
importance of these compounds and their multiple rela-
tionships must be reflected in the human diseasome, the
scope of which is not yet known. This fact impedes devel-
opment of new solutions for diagnosis, prognosis and
treatment of multiple diseases involving the action of bio-
genic amines. This work is a further effort of our group to
integrate genetic, functional and clinic information about
biogenic amine-related diseases assisted by text mining and
network theory-based tools with the aim of helping to
advance in personalized biomedical strategies. Funded by
SAF2011-26518 and AMER (MINECO), and funds from
PAIDI to BIO-267. CIBERER is an initiative of ISCIII
(Spain).
Departmento de Biologı´a Molecular y Bioquimica. Fac-
ultad de Ciencias-Centro de Investigacio´n en Red en
Enfermedades Raras (CIBERER, ISCIII), Universidad de
Ma´laga, Ma´laga, Spain. E-mail: kika@uma.es
TIPS FOR MODELING HISTAMINE RECEPTORS
S. Guccione, M. Pappalardo, M. E. Leonardi, A. Rayan
Histamine receptors belong to class A GPCRs, rhodopsin-
type family. To date, four histamine receptors are known to
be activated by the same endogenous agonist (histamine) and
implicated in various diseases. From a quantitative analysis
of eighteen receptors and subsequently derived 153 pairs of
data, we came to the conclusion that higher sequence identity
between two receptors does not guarantee lower root mean
square deviations (RMSD) between their structures, espe-
cially when pair-wise sequence identity lies between 25 and
40 %. This finding is somehow not in agreement with the
well accepted criterion of choosing as a template the
homologous protein with the highest sequence similarity,
especially if the query protein shares higher than 30 %
sequence identity with the template sequence. Our findings
suggest that receptors having less than 50 % sequence
identity should be considered and evaluated since correlation
is lacking in this range. Additionally, when testing suitability
for structure-based drug design, we found that choosing the
template protein based on the most similar sequence
resemblance only is not justified. Performance in molecular
docking may be taken into account in order to determine
which of the obtained models is likely to be utilized and
mainly based on the enrichment factor criterion. Correlations
between enrichment factors and pair-wise sequence identity
of the various models will be discussed. The H1–H4 recep-
tors’ models which were constructed based on the 18
templates will be described and their efficacy in discrimi-
nating between actives and non-actives was reported.
Departments of Drug Sciences and of Chemical Sciences,
University of Catania, Catania, Italy. E-mail:
a_rayan@qsm.ac.il
INTERSTITIAL DELETION OF HRH1, SLCA1 AND
ATG7 GENES IN A DISABLED PATIENT WITH
OBSERVATION OF JUVENILE IDIOPATHIC
ARTHRITIS
P. Rzodkiewicz, E. Jednacz, A. Kutkowska-Kaz´mierczak,
B. Nowakowska, E. Obersztyn, L. Rutkowska-Sak
3p deletion syndrome is a rare condition caused by deletion
of chromosome 3p25-26. Typical clinical symptoms rela-
ted to this disease are low birth rate, delayed growth,
microcephaly and hypotonia. Small interstitial deletions
occurring at 3p25.3 may help to define critical genes
involved in 3p deletion syndrome. An 11-year-old girl was
hospitalized in National Institute of Geriatrics, Rheuma-
tology and Rehabilitation due to pain, swelling, wrist
ganglions and stiffening of joints. Microcephaly, psy-
chomotor retardation, delayed speech development were
recognized. Preliminary diagnosis suggested juvenile
idiopathic arthritis (JIA). The patient is also under the care
of genetics clinic. Whole genome oligonucleotide
microarray analysis identified small interstitial chromo-
some 3 deletion in the region 11,031,839-11,436,721 -
404 kb. Deletion covers three genes SLCA1, HRH1 and
ATG7. JIA has multifactorial pathogenesis. Genetic factors
have a big influence on risk to develop disease. ATG7 gene
encodes the E1-like activating enzyme involved in the 2
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ubiquitin-like systems involved in MHC-I presentation.
Also, HRH1 may be potentially play a role because clini-
cally active JRA patients show abnormal histamine-
inducible T suppressor cell function, characterized by the
failure of CD8+, CD28-T cells to mediate any
detectable suppression. This case describes for the first
time deletion of histamine H1 receptor in humans. We also
describe the features not previously reported for interstitial
deletions at 3p25.3.
Department of Biochemistry and Molecular Biology,
National Institute of Geriatrics, Rheumatology and Reha-
bilitation, Medical University of Warsaw, Warsaw, Poland.
E-mail: przemyslaw@rzodkiewicz.eu
PARALLEL HIERARCHICAL INTRA-STRAIN
DIFFERENCES BETWEEN THE SUSCEPTIBILITY
TO DIABETIC NEPHROPATHY AND RENAL
HISTAMINE RECEPTOR EXPRESSION
A. Pini, P. L. Chazot, A. C. Rosa
Previously we have demonstrated the renal expression of the
four histamine receptors in both humans and rodents and the
upregulation of both H4R and H3R in the kidney of diabetic
rats. However, intra-species and -strain differences have
been reported for histamine receptors in other tissues.
Notably, it is well known that a hierarchical susceptibility to
diabetic nephropathy exists between DBA/2 C57BL/6 and
Balb/c mice. The aim of this study was to evaluate the
correlation between histamine receptor levels and pattern of
expression with renal function in healthy and diabetic mice
from different inbred strains. Kidneys from DBA/2J,
C57BL/6, and Balb/c 7–8 week-old male mice were pro-
cessed for histamine receptor expression analysis by
immunofluorescence. Pearson correlation analysis between
histamine receptor expression and glycaemic status or renal
function was performed in 15-week diabetic C57BL/6 and
DBA/2J mice versus respective controls. The immunofluo-
rescence analysis demonstrated that both H1R and H4R but
not H3R expression parallels the hierarchical susceptibility
to diabetic nephropathy between DBA/2[C57BL/6[Balb/c
mice. The Pearson correlation between the histamine
receptor expression and the glycaemic status or the renal
functional data (urine volume, proteinuria and albuminuria)
revealed for C57BL/6 a positive correlation for H1R and
H3R and glycaemic status with an r
2 of 0.45 [95 % confi-
dence interval (CI) 0.02–0.92; P\ 0.05] and 0.44 (CI
0.00–0.92; P\ 0.05), respectively. In contrast, DBA/2 mice
showed a strong positive correlation for H4R and
albuminuria with an r2 of 0.97 (CI 0.88–0.99; P\ 0.001).
These data strongly support the role of H4R in diabetic
nephropathy development. The positive correlation between
H3R and urinary volume is in keeping with its localization
on the collecting duct cells. Finally, the data on glycaemic
status raise the question whether histamine receptors could
contribute to the glucose reabsorption mechanism.
Experimental and Clinical Medicine, University of Flor-
ence, Florence, Italy..E-mail: apini@unifi.it
HISTAMINE RECEPTORS LOCALIZATION IN
CILIARY BODIES, RETINAE AND OPTIC NERVE
IN NEW ZEALAND WHITE RABBITS
M. Durante, C. Lanzi, L. Lucarini, A. Pini, E. Masini
Glaucoma is a group of eye diseases characterized by a
steady loss of retinal ganglion cells and irreversible
blindness. Elevated intraocular pressure (IOP) is the hall-
mark of this ocular pathology and it is associated with a
dysfunction of the trabecular meshwork (TM). The reduc-
tion of IOP is considered the target for glaucoma treatment.
Significant histamine levels have been found in retina,
choroid tissue, optic nerves and ocular mast cells. His-
taminergic H3 receptors have been localized in mammalian
ocular structures, such as cones and rods of old world
monkeys. DL-76 (0.5–1 % solution), as well as ABT239,
GSK189254 and Ciproxifan (1 %), proved to be IOP
lowering agents in an acute and chronic model of glaucoma
in New Zealand White (NZW) rabbits, showing features
similar to a reference anti-glaucomatous drug.
The aim of this study was to evaluate the expression and
localization of histamine receptors (HRs) in ciliary body, reti-
nae, optic nerve and TM cells derived from ciliary body to
better understand the roleof thehistaminergic systemin the eye.
We investigated the expression of HRs in ciliary bodies,
retinae and optic nerve by Western blot analysis on
homogenized tissue samples, immunofluorescence staining
on polarized histological slides and in primary trabecular
meshwork TM cell culture.
Western blot analysis demonstrated the presence of
histamine H1, H3 and H4 receptors in ciliary bodies, retinae
and optic nerve, while H2R was not detected. Rabbit
stomach samples were used as a positive control for H2R.
The immunofluorescence staining revealed H1R, H3R and
H4R localization in ciliary bodies, especially on the
endothelium and retinae. Moreover, the expression of these
receptors was detected in TM cells by immunostaining.
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These results provide evidence that HRs could represent a
novel target for the development of a newclass of drugs for the
treatment of inflammatory and hypertensive ocular diseases.
Departments of NEUROFARBA, Section of Pharmacology,
and Experimental and Clinical Medicine, University of
Florence, 50139 Florence, Italy. E-mail: mariaconcetta.
durante@gmail.com
ARE PHENOTHIAZINE-RELATED ADVERSE
DRUG REACTIONS (ADRs) COMPARABLE WITH
ANTIHISTAMINE-RELATED ADRs?
M. Cirronis, M. Conte, C. Lanzi, M. Moschini,
A. Vannacci, E. Masini
New phenothiazine derivatives with antihistaminic effects
were developed in Paris in the 1940s. In the following
years, phenothiazines were proven to exert an antagonistic
effect not only at the histamine H1-receptor level but also at
dopamine D1–D5, serotonin 5HT2A, adrenergic a1 and
muscarinic M1-receptor levels. This study aims to define
whether phenothiazine-related adverse drug reactions
(ADRs) are comparable with first generation anti-H1-re-
lated ADRs. The European Database of Suspected Drug
Adverse Reaction Reports was consulted in order to per-
form the study and all types of active phenothiazine and
antihistamine molecules available in the European market
were investigated.
We found that phenothiazine-neuroleptics and first
generation-anti-H1 ADRs showed similar age and gender
trends. Phenothiazine ADRs for females account
for 50.9 % of cases and male reactions for 45.4 %. In
5.5 % of cases, sex is not reported. In all the samples, the
most involved age group is ‘‘adults between 18–64’’ fol-
lowed by the ‘‘65–85 years old’’ group. Moreover, first
generation neuroleptics presented a high percentage of
nervous system ADRs whilst psychiatric ADRs accounted
for the most common antiallergic medication ADRs.
We can conclude that, in the daily clinical use of all of
these drugs, we have to consider the possible ADRs that
may affect the Central Nervous System. Moreover, in all
the groups a not-negligible percentage of ADRs is related
to potentially serious effects such as cardiac disorders.
Department of Neuroscience, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-
ence, Florence, Italy. E-mail: cirronis.marco@gmail.com
ARE FIRST AND SECOND-THIRD GENERATION
ANTI-H1 ADVERSE DRUG REACTIONS (ADRs)
COMPARABLE?
M. Conte, M. Cirronis, C. Lanzi, M. Moschini,
A. Vannacci, E. Masini
First generation antihistamines are highly lipophilic and
readily cross the blood–brain barrier thereby contributing
to adverse central nervous system effects. In contrast,
second-third generation antihistamines have a higher
specificity for binding to H1 receptors, a lower affinity for
non-histamine receptors and are lipophobic with a corre-
sponding poorer penetration of the blood–brain barrier. The
aim of this study is to demonstrate whether trends in anti-
H1 ADRs involving System Organ Classes (SOCs), age
group and sex are the same between first generation and
second-third generation antihistamines. We accessed data
from ADR Reports, the European Medicines Agency
(EMA) and the European Union Drug Regulating
Authority (EUDRA) joint website. We found 96 antihis-
taminic drugs and associations which are available in the
European drug market. Of these, 73 are first generation
anti-H1 drugs and associations while 23 are second-third
generation. The total number of ADRs from this pool of
drugs is 89,923 for a total of 38,064 patients. Female
patients represent the majority (56.2 % in both groups).
Similar considerations apply to age groups where adults
between 18–64 years are the most represented (63.9 vs
47.5 %). Among SOCs, we see a similar trend especially
regarding the predominance of nervous system and psy-
chiatric disorders (27.6 % vs 19.8 %). Other SOCs
involved in the first generation anti-H1 group ADRs are
‘‘injury, poisoning and procedural conditions’’ (15.7 %)
and ‘‘general disorders and administration site conditions’’
(10.7 %). In second-third generation anti-H1 ADRs, other
relevant SOCs involved are ‘‘general disorders and
administration site conditions’’ (11.7 %) and ‘‘skin and
subcutaneous tissue disorders’’ (8.9 %). In conclusion,
ADR analysis in both groups shows the same trends
regarding age, sex and predominance of nervous and psy-
chiatric disorders, suggesting an important action of
second-third generation antihistamines on the central ner-
vous system.
Department of Neuroscience, Psychology, Drug Research
and Child Health (NEUROFARBA), University of Flor-
ence, Florence, Italy. E-mail: marconte89@gmail.com
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PHOSPHO-Src PROTEIN MEDIATES RADIO-
INDUCED MESENCHYMAL CHANGES IN MCF-7
CELLS: MODULATION BY HISTAMINE
T. Galarza, M. Ta´quez Delgado, N. Mohamad, G. Vedoya,
V. Medina, G. Martı´n, G. Cricco
Radiotherapy is a prime option for treatment of solid
tumors though an increase in invasiveness of neoplastic
cells has been described and associated with induction of
epithelial to mesenchymal transition (EMT). Our previous
findings show that histamine may reduce the manifestation
of mesenchymal features in irradiated MCF-7 and MDA-
MB-231 breast cancer cells. We also determined that
phosphorylation/activation of Src kinase is involved in
histamine modulated MDA-MB-231 cell migration and
invasion. The aim of this work was to investigate the role
of phospho-Src (P-Src) in irradiated MCF-7 cells in rela-
tion to the invasive phenotype when cells were previously
treated with histamine. Cells were treated with 20 lM
histamine, 10 lM PP2 (Src inhibitor) or histamine + PP2
for 24 h, and then were irradiated with a dose of 2 Gray
which is comparable to that used in fractionation radio-
therapy. P-Src levels were determined immediately after
irradiation while experiments to evaluate EMT molecular
markers and cell migration were performed 5 days post-
irradiation. Immunoblots show that ionizing radiation
produced an increase in P-Src protein level (p\ 0.05, one
way ANOVA and Bonferroni). Moreover, histamine, PP2
or histamine + PP2 reduced P-Src levels (p\ 0.05).
Immunofluorescence studies show E-cadherin and Beta-
catenin mainly in the cytoplasm of irradiated cells while
membrane-localized E-cadherin and Beta-catenin were
observed when MCF-7 cells were treated with histamine,
PP2 or the combined treatment 24 h prior to gamma irra-
diation. The migratory capacity was studied using transwell
units. Results were in agreement with P-Src levels deter-
mined above supporting the role of this activated kinase in
irradiated MCF-7 cell migration and its modulation by
histamine (p\ 0.05). The association between histamine
and ionizing radiation may be a challenge to further
investigate and identify new targets with therapeutic
potential to prevent the invasive phenotype in tumors and
also enhance radiotherapy effectiveness.
Laboratory of Radioisotopes, School of Pharmacy and
Biochemistry, University of Buenos Aires, Buenos Aires,
Argentina. E-mail: vaninamedina78@gmail.com
HISTAMINE POTENTIATES IONIZING
RADIATION-INDUCED DNA DAMAGE IN VITRO
AND IN VIVO IN HUMAN TRIPLE NEGATIVE
BREAST CANCER
D. Martinel Lamas, M. Nicoud, J. C. Perazzo, E. Rivera,
V. Medina
We previously demonstrated that histamine selectively
increases the radiosensitivity of different human cancer cell
lines (MDA-MB-231, MCF-7, 1205Lu). The aims of this
work were to investigate the combined effect of histamine
and gamma radiation in vitro on markers of DNA damage
and activity of antioxidant enzymes of two triple negative
breast cancer (TNBC) cell lines (MDA-MB-231 and MDA-
BrM2) and to evaluate the histamine-induced radiosensi-
tization in vivo in MDA-MB-231 TNBC model. Results
demonstrate that histamine enhanced radiosensitivity of
MDA-BrM2 cells, which display increased brain metastatic
activity, mainly through the H1R as previously described
for MDA-MB-231 cells. In addition, histamine increased
radiation (2 Gy dose)-induced genotoxic activity in both
cell lines as evidenced by an enhanced number of cH2AX
foci (marker of DNA double-strand breaks) per cell
(4.5 ± 0.9 in control, 23.3 ± 1.7 in 2 Gy-untreated and
33.1 ± 1.9 in 2 Gy-histamine, P\ 0.01 in MDA-BrM2
cells and 13.3 ± 1.4 in control, 33.0 ± 1.9 in 2 Gy-un-
treated and 41.1 ± 1.7 in 2 Gy-histamine, P\ 0.05 in
MDA-MB-231 cells) and also an increased 8-OHdG for-
mation (marker of oxidative DNA damage) (one way
ANOVA and Newman–Keuls tests). These effects were
associated with the increased production of reactive oxy-
gen species and the modulation of activity of antioxidant
enzymes (catalase, glutathione peroxidase, superoxide
dismutase). Histamine was also able to potentiate in vivo
the anti-tumoral effect of radiation. Radiation administered
as three doses of 2 Gy in consecutive days showed only
modest non-significant reduction of tumor size while his-
tamine treatment (injected sc from 1 day before irradiation
until the end of the experiment) produced a 2-fold decrease
in size (P\ 0.05) and increased exponential doubling time
of irradiated tumors. We conclude that histamine increases
the response of TNBC cells to radiation, suggesting that it
could be used as a potential adjuvant to enhance the effi-
cacy of radiotherapy.
Institute for Biomedical Research (BIOMED CONICET-
UCA), School of Medical Sciences, Pontifical Catholic
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University of Argentina (UCA), Buenos Aires, Argentina.
E-mail: vaninamedina78@gmail.com
HISTAMINE MODULATES TUMOUR GROWTH
AND ANTITUMOUR IMMUNITY IN 4T1 TRIPLE
NEGATIVE BREAST CANCER DEVELOPED IN
H4R KNOCK-OUT (H4R KO) AND WILD-TYPE
(WT) BALB/c MICE
H. Sterle, M. Nicoud, D. Martinel Lamas, J. C. Perazzo,
G. Cremaschi, V. Medina
It is well-known that histamine regulates cellular immune
responses, affecting maturation and activity of lympho-
cytes and myeloid-derived suppressor cells, which are
considered as potential effectors of antitumor immunity
and may interfere with tumor progression. The aim of the
present work was to investigate the influence of the lack of
histamine H4 receptor (H4R) on the tumorigenic capacity,
metastatic potential and antitumor immunity in response to
histamine in a triple negative breast cancer (TNBC) model.
Thus, we evaluated tumor growth parameters, the pheno-
type of splenic and intra-tumoral lymphocytes in syngeneic
H4R knock-out (H4R KO) and wild-type (WT) mice,
inoculated orthotopically with 4T1 murine TNBC cells.
CD4+, CD8+, CD11b+, C19+, CD3+, NK1.1+ cells were
quantified in the spleens and tumors by flow cytometry.
Results indicate that histamine (0.1–10 lM) produced a
2-fold decrease in proliferation evaluated by BrdU-incor-
poration without inducing significant apoptosis in vitro in
4T1 TNBC cells. We observed non-significant differences
in latency period or tumor growth between WT and KO
mice while spleen weight was significantly higher in WT
than in KO mice. Histamine (1 mg/kg.day s.c.) reduced
tumor volume in KO mice (743 vs. 1045 mm3 after
15 days of treatment, *P\ 0.05, ANOVA and Newman–
Keuls post-test). In conclusion, the present study demon-
strates that histamine regulates the growth of TNBC and
the modulation of tumor immunity seems to be involved in
histamine effects.
Institute for Biomedical Research (BIOMED CONICET-
UCA), School of Medical Sciences, Pontifical Catholic
University of Argentina (UCA), Buenos Aires, Argentina.
E-mail: vaninamedina78@gmail.com
HISTAMINE REDUCES THE INCIDENCE OF
SEVERE MUCOSITIS INDUCED BY BORON
NEUTRON CAPTURE THERAPY (BNCT) IN FIELD
CANCERIZED TISSUE IN THE HAMSTER CHEEK
POUCH ORAL PRECANCER MODEL WITHOUT
COMPROMISING THERAPEUTIC EFFICACY
A. Monti Hughes, E. C. C. Pozzi, S. Thorp, P. Curotto,
V. A. Medina, D. J. Martinel Lamas, E. S. Rivera,
M. A. Garabalino, R. O. Farı´as, S. J. Gonza´lez,
E. M. Heber, M. E. Itoiz, R. F. Aromando, D. W. Nigg,
V. A. Trivillin, A. E. Schwint
BNCT is based on the capture reaction between boron-10,
selectively targeted to tumor tissue, and thermal neutrons
which gives rise to lethal, short-range high linear energy
transfer particles that selectively damage tumor tissue. We
demonstrated that the double application of BNCT medi-
ated by the boron compounds BPA + GB-10 [D(GB-
10 + BPA)-BNCT], 4 weeks between applications, 10 Gy
total absorbed dose, had the best therapeutic effect in the
hamster cheek pouch oral precancer model but induced
severe mucositis in field cancerized tissue. In a clinical
scenario, the reduction of oral mucositis is an unmet
medical need, limiting tumor dose and affecting patients´
quality of life. We previously demonstrated for the first
time the radioprotective effect of histamine in BNCT
treated animals, employing BPA, without compromising
BNCT therapeutic effect. The aim of the present study was
to evaluate the effect of histamine in D(GB-10 + BPA)-
BNCT treated animals employing 2 protocols. DMBA-
cancerized hamsters were treated with: (1) BNCT without
Histamine; (2) BNCT + Histamine LOW concentration
(1 mg/kg/day)–LONG administration (16 days); (3)
BNCT + Histamine HIGH concentration (5 mg/kg/day)-
SHORT administration (5 days). We evaluated histamine
toxicity, % of animals with severe mucositis and % of
animals with new tumors after BNCT, up to 3 months after
the first irradiation at RA3 nuclear reactor. At the last time-
point, the percentage of animals with severe mucositis and
new tumors were analyzed using a contingency table and
Fisher’s exact test (p\ 0.05). Local irritation was seen at
the site of histamine injection. Protocols 2 and 3 exhibited
a trend (albeit not statistically significant) to reduce severe
mucositis versus group 1 (Respectively: 29 %; 20 %;
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33 %), without compromising therapeutic effect vs group 1
(p = 1.0000). Protocol 3 showed a tendency to have a
greater protector effect than protocol 2. Histamine HIGH
concentration-SHORT administration could be more
effective to reduce the incidence of severe mucositis in
field cancerized tissue treated with D(GB-10 + BPA)-
BNCT. Furthermore, this protocol involves fewer appli-
cations, reducing animal handling and the local irritation
caused by the injection.
Dpto. Radiobiologı´a, Gcia. Quı´mica Nuclear y Cs. de la
Salud, GAATEN, CNEA.–General Paz 1499 (B1650KNA)
San Martı´n, Buenos Aires, Argentina. E-mail:
andre.mh@gmail.com; vaninamedina78@gmail.com
SERUM HISTAMINE AND CYTOKINE LEVELS IN
CANCER PATIENTS UNDERGOING
DESENSITIZATION TO CARBOPLATIN: A PILOT
STUDY
M. Makris, N. Gkavogiannakis, M. Grosicki, E. Tiligada
The wide exploitation of platinum-containing chemothera-
peutic agents in malignancies is coupled with increasing
incidence of unforeseen hypersensitivity reactions. These
potentially fatal complications have been associated with
histamine-mediated type I and/or T cell-mediated type IV
responses. However, the underlying mechanisms remain
elusive, while desensitization is the only management
option when replacement agents are related with poor
prognosis. This pilot study aimed to explore the contribu-
tion of circulating histamine, TNF-a and IL-6 in IgE-
mediated reaction to carboplatin. Three selected cancer
patients (1 female; 2 male, 64–68 years of age) with a well-
documented reaction to carboplatin were offered carbo-
platin skin testing and received scheduled chemotherapy
cycles with desensitization sessions. Two of them had a
hypersensitivity reaction during at least one desensitization
session. A healthy volunteer undergoing ranitidine desen-
sitization served as control. Serum histamine levels were
quantified fluorophotometrically and TNF-a and IL-6 were
determined by ELISA in all subjects. Basal serum his-
tamine and IL-6 levels were higher, while TNF-a levels
were lower in cancer patients compared to the control.
Interestingly, serum histamine levels increased after rani-
tidine desensitization but remained unchanged during
desensitization to carboplatin. Conversely, TNF-a levels
significantly increased (p\ 0.05) in carboplatin but not in
ranitidine desensitization, while IL-6 levels showed incon-
clusive variations. Despite the small sample size, the
consistency of the findings suggests that the implication of
circulating inflammatory mediators in drug allergy and in
the desensitization process may depend on the medication
and/or on the disease pathophysiology. Furthermore, they
support the need for a more systematic and careful inves-
tigation of specific symptomatic and/or aetiologic
mechanisms underlying drug hypersensitivity reactions.
MG received a grant from COST BM1007 to perform a
STSM at NKUA.
.Department of Pharmacology, Medical School,
National and Kapodistrian University of Athens, Athens,
Greece. E-mail: atiligada@med.uoa.gr
CARDIAC H2 RECEPTOR OVEREXPRESSION
PROTECTIVE AGAINST PP2A MEDIATED HEART
FAILURE
J. Neumann, F. Bergmann, U. Gergs
We have generated mice which overexpress the catalytic
subunit of protein phosphatase 2A, a serine/threonine
phosphatase exclusively in the heart by use of the myosin
heavy chain promoter (PP2A). This led to increase PP2A
enzyme activity and dephosphorylation of cardiac regula-
tory proteins, for instance, phospholamban and troponin
inhibitor. Moreover, PP2A overexpressing mice exhibited a
time dependent cardiac hypertrophy. On the other hand,
histamine can exert positive inotropic and chronotropic
effects in humans via H2 histamine receptors. We have also
generated transgenic mice (H2) which overexpress the
human H2 receptor in specifically in cardiomyocytes via the
alpha MHC promoter. In these mice but not in wildtype
mice (WT) histamine induced increases in heart rate and
ejection fraction. We crossed these mice with mice over-
expressing the catalytic subunit of protein phosphatase 2A
(PP2A) leading the double transgenic mice (H2 -
9 PP2A = DT). After about 240 days we noted reduced
left ventricular ejection fraction (EF) in PP2A
(33.14 ± 3.54 %, n = 16) compared to WT (54.41 ±
4.46 %, n = 10) and H2 (59.81 ± 2.88 %, n = 10). Inter-
estingly, in DT (43.85 ± 4.87 %, n = 11) EF was higher
than in PP2A, despite similar heart rates. E´/A´ was elevated
in DT compared to WT. Relative heart weight was
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unchanged between these groups. We tentatively conclude
that the histamine H2 receptor is able to ameliorate systolic
but not diastolic cardiac function of PP2A mice.
Institute for Pharmacology and Toxicology, Medical Fac-
ulty, Martin-Luther-University Halle-Wittenberg, 06097
Halle (Saale), Germany. E-mail: joachim.neu-
mann@medizin.uni-halle.de
DIAMINE OXIDASE AND MONOAMINE OXIDASE
CAN DEGRADE HISTAMINE IN THE
MAMMALIAN HEART TO AN INOTROPICALLY-
RELEVANT EXTENT
U. Gergs, J. M. Grobe, J. Neumann
Histamine is metabolized by several enzymes in vitro and
in vivo. The relevance of this metabolism in the mam-
malian heart in vivo is unclear. However, histamine can
exert positive inotropic effects (PIE) and positive chrono-
tropic effects (PCE) in humans via H2 histamine receptors.
We have generated transgenic mice (TG) which overex-
press the human H2 receptor specifically in cardiomyocytes
via the a-myosin heavy chain promoter. In these mice, but
not in wild type mice (WT), histamine induced PIE and
PCE in isolated left or right atrial preparations. This mouse
model was used to generate data on the relevance of his-
tamine-degrading enzymes in the heart. Interestingly, the
inhibitor of histamine oxidation, aminoguanidine (1 mM),
shifted the log concentration response curves for the PIE to
the left from EC50 = 110 nM to 37 nM (n = 4–6;
p\ 0.05). Furthermore, the unspecific inhibitor of mono-
amine oxidase, tranylcypromine (10 lM), shifted the PIE
of histamine from EC50 = 70 nM to 38 nM and increased
the efficacy of histamine for the PIE from a maximum
response of 9.3 ± 0.8–12.4 ± 0.2 mN (n = 3–4;
p\ 0.05). These data indicate that exogenously applied
histamine is subject to degradation in the mammalian heart
by two different pathways namely diamine oxidase and
monoamine oxidase. It is conceivable that drugs that
inhibit these enzymes may alter cardiac function in the
human heart for example via enhanced effects of
histamine.
Institute for Pharmacology and Toxicology, Medical Fac-
ulty, Martin Luther University Halle-Wittenberg, Halle
(Saale), Germany. E-mail: Ulrich.gergs@medizin.uni-
halle.de
A NOVEL SIGNALING PATHWAY CONNECTING
THYROID HORMONE DERIVATIVES WITH THE
HISTAMINERGIC SYSTEM
A. Laurino, L. Raimondi
We previously reported that 3-iodothyroacetic acid (TA1),
one of the byproducts of thyroid hormone metabolism, is
endowed with rapid, non-genomic, pharmacological effects
including stimulation of learning, hyperalgesia and an
increase in plasma glycaemia. Interestingly, these effects
were also shared by 3-iodothyronamine (TIAM, the trace
amine generating TA1), and were dependent on histamine
release, thus allowing us to assume that T1AM and TA1
behave as endogenous neuromodulators of the histamin-
ergic system. Currently, the clinical impact of such
evidence is largely unknown. However, the clinical mani-
festations of thyroid diseases include itch, altered pain
sensation to thermal stimuli and disturbance in the sleep/
awake cycle. Exploring the hypothesis that accumulation of
TA1 might be involved in such effects, we aimed to verify
whether TA1 might induce pruritus, increased mice
awaking time and modify the threshold to noxious heat
stimuli. Itch was evaluated after s.c. administration of
saline or TA1 (0.4, 1.32 and 4 lg kg-1) in the absence or
in the presence of pyrilamine (10 mg kg-1; s.c.). The
threshold of mice to noxious heat temperature (NHT) was
evaluated by the increasing-temperature hot plate method
(from 45.5 to 49.5 C) 15 min after i.p. injection of TA1
(0.4, 1.32 and 4 lg kg-1). Spontaneous and
exploratory activities were evaluated by the hole-board test
10 min after i.p. injection of TA1 (0.4, 1.32, 4 lg kg-1).
Itch and NHT were also measured in HDC+/+ and HDC-/-
mice following injection of saline or TA1 (1.32, 4 and
11 lg kg-1; i.p.). The awaking effect of TA1 was evalu-
ated in mice receiving a single hypnotic dose of ethanol
(3.5 g kg-1, i.p.). At this setting, the time latency of the
onset of sedation (LORR latency) and recovery from it
(LORR duration) were measured. TA1 (0.4 and
1.32 lg kg-1) induced itch and reduced the NHT. These
effects were prevented in mice pre-treated with pyrilamine
and were absent in HDC-/- mice. TA1 (4 lg kg-1; i.p.)
increased spontaneous motility of mice and significantly
increased LORR latency while reducing LORR duration.
Our results confirm that TA1 pharmacologically injected
into mice induces peripheral and central histamine-related
effects, reinforcing the evidence of the existence of a novel
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endogenous signaling connecting the thyroid with the his-
taminergic system.
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EFFECTS OF OLEOYLETHANOLAMIDE SUB-
CHRONIC TREATMENT ON FOOD INTAKE,
BODY WEIGHT AND GUT MICROBIOTA
COMPOSITION IN NORMAL AND HISTAMINE
DEFICIENT MICE: A PRELIMINARY STUDY
G. Provensi, E. Conti, L. Pavarini, A. Costa, C. De Filippo,
M. B. Passani
Energy balance is an equilibrium between the amount of
energy extracted from the diet and the amount expended
and is regulated by a complex interplay between central
and peripheral factors. We demonstrated that the fat-
derived satiety factor oleoylethanolamide (OEA) requires
the integrity of the central histaminergic system to fully
exert its hypophagic action. Recent evidence suggests that
the gut microbiota play a role in energy harvest, storage,
and expenditure and its composition was shown to differ in
lean and obese humans and animals and to change rapidly
in response to dietary factors. Here we evaluate the effects
of OEA sub-chronic treatment on food intake, body weight
and gut microbiota composition as well as investigate the
role of the histaminergic system in such effects. Histidine
decarboxylase knock out (HDC-KO) mice and wild type
(WT) littermates received daily i.p. injections of OEA
(10 mg/kg, n = 4–5) or vehicle (PEG:Tween80:saline 5/5/
90, n = 4–5) for 11 days, 1 h before dark onset. Faecal
samples were collected after the 1st, 4th and 11th treatment
day. DNAs were extracted and sequenced on a Roche 454
GS FLX? platform for the analysis of the V3–V5 region of
the bacterial 16SrRNA gene. Food consumed 1 h after
OEA treatment and cumulative food consumption at the
end of treatment were significantly reduced in WT mice,
with respect to vehicle-treated controls, but not in HDC-
KO mice. A significant reduction in body weight was also
observed in OEA-treated WT mice with respect to vehicle-
treated animals, while no significant changes were
observed in OEA-treated HDC-KO mice with respect to
controls. In agreement with the decrease of weight, an
enrichment of the phylum Bacteroidetes and a reduction of
Firmicutes emerged in the group of OEA-treated WT mice.
This trend in terms of phyla, is associable to the appearance
of a ‘‘lean’’ microbiota instead of an ‘‘obese’’, where the
trends of the two phyla are reversed. We acknowledge the
Joint Programming Initiative—A Healthy Diet for a
Healthy Life for support of AMBROSIAC project.
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HISTAMINE IN PROBIOTIC YOGURTS
K. Chojnacka, A. Mertas, W. Kro´l, J. Jochem
Probiotic yogurts are produced using cultures of Lacto-
bacillus delbrueckii subsp. bulgaricus and Streptococcus
thermophilus bacteria which evoke the fermentation of milk.
In addition, they contain live micro-organisms which confer
a health benefit on the host, added during or after culturing
yogurt. Since all these bacteria may express histidine
decarboxylase activity, the aim of this study was to examine
histamine concentration in probiotic yogurts. Histamine
levels and the ability to synthesis histamine by bacteria
present in five commercially available in Poland probiotic
yogurts at the beginning and the end of their shelf life were
measured using ELISA kits (Beckman Coulter) and a
microplate spectrophotometer (EonTM, BioTek). Histamine
concentrations at the end of the shelf life ranged from
0.570 ± 0.05 to 1.101 ± 0.03 lg/ml and were significantly
higher (p\ 0.05, paired Student’s t-test) than at the begin-
ning of their shelf life (0.413 ± 0.01–1.019 ± 0.03 lg/ml).
Interestingly, histamine levels in cultures with L-histidine
(4 g/l) supplementation were 9–10 times higher (p\ 0.001,
paired Student’s t-test) in comparison to controls (MRS
Broth) without L-histidine supplementation. Therefore: (1)
histamine concentration in probiotic yogurts increases with
the storage time and (2) the addition of probiotic yogurts to
food products containing high concentrations of L-histidine
may result in consumption of large amounts of histamine.
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